Download 1 Bradley A. Bart, MD, FACC 5. TEACHING a. Percent effort

Bradley A. Bart, M.D., F.A.C.C.
5. TEACHING
a. Percent effort - 25% b. Narrative summary
Since joining the faculty in 1997, I have been engaged with teaching at all levels of graduate
medical education through my involvement with medical students at the University of
Minnesota; residents from the Internal Medicine, Family Medicine, and Emergency Medicine
residency training programs at HCMC; cardiology fellows from the University of Minnesota;
and, more recently, from a new fellowship training program in cardiovascular disease based at
HCMC.
FELLOWS
HCMC was one of the key sites for clinical rotations for the University of Minnesota cardiology
fellowship until 2010. From 2001 to 2010, I served as the site rotation director for the
cardiology fellows' clinical rotations at HCMC, coordinating the rotations, educational
programing, and evaluations for the University fellows that rotated at HCMC (36 fellow
rotations per year). I also served on the fellowship selection committee for the University of
Minnesota and committed approximately 30 hours per year reviewing application folders,
interviewing prospective fellows, and ranking fellows for the match in committee meetings that
took place every Fall. From 2002 to 2007, I was the Director of Nuclear Cardiac Imaging at the
University of Minnesota, developed the nuclear cardiology curriculum for the University
fellows, and taught the fellows weekly on site at the University of Minnesota. In addition to
these leadership roles within the University fellowship program, I rounded and taught University
fellows during their rotations at HCMC 10 weeks per year on the inpatient cardiology
consultation service, once a week year round in the cardiac catheterization laboratory until 2008,
and 1/2 day per week in the fellows' continuity clinic. I was also asked to lecture regularly on
heart failure and nuclear cardiac imaging to the fellows during their weekly core curriculum
sessions. In 2006, I was recognized as 'Teacher of the Year' by the University of Minnesota
cardiology fellows.
In 2010, I completed the ACGME Program Information Form (PIF) and application for a
fellowship training program in cardiovascular disease based at HCMC. The application was
successful and we became one of four newly accredited cardiovascular training programs in the
United States that year. I am the fellowship Program Director, the chair of the fellowship
Clinical Competency Committee, the chair of the Program Evaluation Committee, and serve on
the HCMC Graduate Education Committee. We recruited our first class of entering Fellows in
2011 and will be graduating this inaugural class in June 2014. One graduating fellow will be
starting an interventional fellowship at Duke University after graduation and the other fellow
will be starting an electrophysiology fellowship at Kaiser Permanente. This fellowship has been
a successful collaboration with the GME office at HCMC, the internal medicine residency
program at HCMC, and the Minneapolis Heart Institute, the major rotating site outside HCMC.
Our fellowship training program combines the history and culture of a public safety net and
1 teaching hospital (HCMC) and the strengths and procedural volumes of a thriving cardiology
private practice - part of one of the largest referring networks in the state.
The responsibility of the Program Director is oversight of all the educational content for the
fellows as well as adherence to all the ACGME program requirements. I established 12 clinical
rotations between two major hospitals, a research elective, and an international experience
available to all fellows. I also established a weekly core curriculum involving 1 month of boot
camp directed toward incoming fellows and a 40 week program divided into 4 major educational
themes involving 10 lectures each: ischemic heart disease, heart failure, electrophysiology, and
valvular/congenital heart disease. In addition to these leadership responsibilities, I continue to
teach the fellows directly in the setting of weekly conferences, journal club, ECG reading
sessions, and core lectures. In addition, I am the rotation director of the nuclear cardiology and
advanced imaging rotation (2 months per year) and am a clinic preceptor for a cardiology
fellow's continuity clinic (1/2 day per week). I also teach the fellows during the inpatient
cardiology consultation service (10 weeks per year, 10 fellows per year).
RESIDENTS
In addition to my responsibilities as program director for the training program in cardiovascular
disease, I maintain direct teaching responsibility in a number of clinical services in the hospital. I
am the attending on the inpatient cardiology consultation service 10 weeks a year. This is a
traditional academic rotating consultative service involving one fellow, three residents, and two
medical students (approximately 60 trainees per year). I am a preceptor for residents interested
in gaining experience in the Early Access cardiology clinic. I also give core lectures for the
Internal Medicine residency program on heart failure and stress testing each year.
MEDICAL STUDENTS
I enjoy working with University of Minnesota second-year medical students in the small group
sessions of the second year pathophysiology course on cardiovascular disease. Each year I lead a
small group of 20 to 30 students through 3 to 6 sessions. For a number of years, I gave the heart
failure and cardiomyopathy lectures in the 2nd year pathophysiology course at the University of
Minnesota. I also teach medical students on the inpatient cardiology consultation service 10
weeks per year.
RESEARCH WITH TRAINEES
I have worked with residents and fellows on a number of clinically related research topics and
these papers have been published or presented at national meetings in the following areas:
nuclear cardiac imaging and balanced ischemia, prosthetic valve thrombosis, atrial fibrillation,
radiation-induced myocardial stunning, use of therapeutic hypothermia in out of hospital cardiac
arrest patients, the appropriateness of routine head CT scanning for out of hospital cardiac arrest
patients, troponin elevations and pulmonary embolism, pulmonary hypertension, the effects of
external counterpulsation on peripheral arterial disease, heart failure hospitalizations in cocaine
users, the occurrence of coronary artery aneurysms in cocaine users, ultrafiltration, carotid artery
stiffness, the use of mineralocorticoid receptor antagonists in heart failure, and the occurrence of
a rare complication from septal myomectomy.
2 c. Teaching Experience
Teaching Table
I. Undergraduates
Course
Role
Hours of time/year
(number of lectures, etc)
# of Students
Years Taught
Course
Role
Hours of time/year
(number of lectures, etc)
# of Students
Years Taught
Year II Med School
Pathophys heart failure
talk
Year II Med School
Pathophys sm group
sessions
Cardiology consult
service
Core curriculum stress
testing/heart failure
HCMC
Speaker
2 per year
Total 1000
8
Speaker/
facilitator
3-6 per year
Total 900
13
Attending
10 weeks per year
Total 320
16
Speaker
2 per year
Total 850
16
Role
Hours of time/year (number of
lectures, etc)
# of Students
Years Taught
Cardiorenal syndrome
U of M and HCMC
Myocardial viability
U of M
Myocardial perfusion
imaging U of M
Cardiology consult
service HCMC
Friday School Intern
program HCMC
Core curriculum stress
testing/heart failure
HCMC
Nuclear cardiology
U of M and HCMC
Cardiac catheterization
laboratory
Cardiology clinic
Speaker
1 per year
Total 30-100
5
Speaker
1 per year
Total 72-240
12
Speaker
2 per year
Total 60-200
10
Attending
10 weeks per year
Total 640
16
Speaker/facilitator
1 per year
Total 50
3
Speaker
2 per year
Total 850
16
Rotation Director
2-6 months per yr
Total 70
7
Procedural
attending
Preceptor
44 days/year
Total 120
11
½ day/week
Total 6
IV. Other
Teaching/Activities
(list)
Medicine Grand
Rounds
Web-based learning –
MIBI of the Month
CV fellowship – all
educational aspects
Role
Hours of time/year (number of
lectures, etc.)
# of Students
Years Taught
Speaker
Various topics – 17 over the years
Total 800-1600
16
Content leader
1 per month
Total 1200
5
Program Director
25% overall time
Total 14
3
None
II. Graduates
III. Pre/Post-Doctoral
Classroom or Clinical
3 Mentoring/Training Table
I. Undergraduate Students
Role
Trainee
Name
Training
Period
Where Trained
Project
Academic
Level of
Trainee
Present Position and
Institution
Training
Period
Where Trained
Project
Academic
Level of
Trainee
Present Position and
Institution
Project
Present Position and
Institution
None
II. Graduate Trainees
Role
Trainee
Name
None
III. Post-Doctoral Trainees
Role
Trainee
Name
Training
Period
Where Trained
Program
Director
Program
Director
Program
Director
Ben Johnson
2014
HCMC
Academic
Level of
Trainee
PGY 4
Michelle
Carlson
Sarah
Thordsen
2014
HCMC
PGY 4
2013present
HCMC
Program
Director
Program
Director
Program
Director
and clinic
preceptor
Yader
Sandoval
Amatul
Hassan
Ankur Kalra
2013present
2012present
2012present
HCMC
Program
Director and
clinic
preceptor
Program
Director and
clinic
preceptor
Advisor and
research
mentor
Clinic
preceptor
Clinic
preceptor
Louis Kohl
20112014
HCMC
Hemal
Kadakia
20112014
Imdad
Ahmed
Cardiology Fellow –
HCMC
Cardiology Fellow –
HCMC
Cardiology Fellow –
HCMC
Eplerenone use in
chronic heart failure
JACC 2013
QTc intervals in
hypothermia
Career and research
advisor
Aorto-right atrial
fistula after cardiac
surgery
Echocardiography
2012
Career and research
advisor
PGY 4,5
HCMC
Career and research
advisor
PGY 4-6
EP Fellow – Kaiser
Permanente, LA,
California
2010
Regions
Heart failure in
cocaine users JCF
2010
Electrophysiology Yale
Joseph
Browning
Santiago
Garcia
20092010
20082009
U of Minnesota
Hospitalists
with Health
Partners
PGY 4-6
U of Minnesota
PGY 4-6
Clinic
preceptor
Darshak
Karia
20032005
U of Minnesota
PGY 4-6
Advisor and
research
collaborator
Marit
Thorsgard
20062009
HCMC
HCMC
HCMC
Ultrafiltration for
heart failure
Congest Heart Fail
2009
4 PGY 4,5
PGY 4-6
PGY 4-6
PGY 4-6
PGY 4-6
Cardiology Fellow –
HCMC
Cardiology Fellow –
HCMC
Cardiology Fellow –
HCMC – accepted to
Interventional CV
Fellowship – Beth
Israel, Boston
Interventional CV
Fellow – Duke
University
Cardiology – Health
Partners
Interventional
Cardiology –
Minneapolis VAMC
Heart Failure specialists
–Einstein Medical
Center, Philadelphia
Interventional
Cardiology – Health
Partners
Advisor and
research
mentor
Gautam
Shroff
20032006
HCMC
Clinic
preceptor
Ganesh
Raveendrum
20022003
U of Minnesota
Advisor and
research
collaborator
Aimee
Koralesky
19992002
HCMC
Advisor and
research
mentor
James Mohn
19992002
U of Minnesota
Advisor and
research
collaborator
Aaron
Satran
19972000
HCMC
Advisor and
imaging
mentor
James
Montana
1999
HCMC
Training
Period
Where Trained
Carotid artery
stiffness and risk of
coronary heart
disease ACC 2005,
J of Hum Hypertens
2009
PGY 1-3
Echo director - HCMC
PGY 4-6
Interventional
Cardiology and
Program Director, U of Minnesota
Non-invasive
Cardiology –
Minneapolis
Role of troponin I in
predicting outcomes
after pulmonary
embolism World
Congress, Australia
2002, JACC 2002
Echocardiographic
correlates of
pulmonary
hypertension ACC
2004
Incidence of
coronary artery
aneurism formation
in cocaine users
ACC 1998,
Circulation 1999
Level II training in
nuclear cardiology
PGY 1-3
Project
PGY 4-6
Interventional
Cardiology - St. Luke’s
Cardiology, Duluth
PGY 1-3
Interventional
Cardiology – Louisville
Heart Specialists
PGY 7
Primary Care –
Essential Health
Academic
Level of
Trainee
Present Position and
Institution
IV. Junior Faculty Trainees
Role
Trainee
Name
See above
Teaching/Instructional/Educational Activity
University of Minnesota
Course/Lecture List
 “Cardiorenal Syndrome and Ultrafiltration,” University of Minnesota Cardiology Fellowship
Training Program Core Conferences, University of Minnesota, Minneapolis, Minnesota, 2012.
 “Ultrafiltration: How, In Whom, and When to Do It?” Bakken Symposium 2010: Heart
Failure, University of Minnesota, Minneapolis, Minnesota, December 6, 2010.
 “Myocardial Perfusion Defects,” University of Minnesota, Minneapolis, Minnesota,
December 2010.
 “Stress Testing in ESRD Patients,” Imaging Conference, University of Minnesota,
Minneapolis, Minnesota, January 27, 2010.
 “Valvular Heart Disease,” Clinical Cardiology Conference, Hennepin County Medical Center,
Minneapolis, Minnesota, 2010.
 “Pathogenesis of Atherosclerosis,” Surgery Didactic Curriculum, Hennepin County Medical
Center, Minneapolis, Minnesota, January 6, 2009.
5  “Nuclear Stress Testing in Clinical Decision Making,” Internal Medicine Grand Rounds,
University of Minnesota, Minneapolis, Minnesota, 2005.
 “Setting Up and Running of Stress Lab in Primary Care,” 5th Annual Lillehei Symposium,
University of Minnesota, Minneapolis, Minnesota, 2004.
 “Stress Testing Basics: Nuclear Stress Tests,” 5th Annual Lillehei Symposium, University of
Minnesota, Minneapolis, Minnesota, 2004.
 “External Counterpulsation for the Treatment of Angina Pectoris,” Research Conference,
Fairview-University Medical Center, Minneapolis, Minnesota, 2002.
 Year II Medical School Pathophysiology Course lectures on cardiomyopathy and heart failure
(two lectures) each year from 2001 to 2008 (150 students per lecture).
 “Assessment of Myocardial Viability,” Interventional Cardiology Conference, University of
Minnesota, Minneapolis, Minnesota, annually from 2000 to 2012.
 “Myocardial Perfusion Imaging” Core Curriculum, University of Minnesota Fellowship in
Cardiovascular Disease, two lectures per year annually from 2000 to 2010.
 “Myocardial Profusion Imaging: Update and Prognostic Implications,” Grand Rounds,
University of Minnesota, Minneapolis, Minnesota, 2000.
 Year II Pathophysiology Small Group Sessions – 20-30 students per session, 3-6 sessions per
year, from 1991 to present.
Curriculum Development
 Pilot project for Cardiology Fellows’ end of rotation evaluations involving educational
milestones encompassing the 6 ACGME core competencies, Hennepin County Medical
Center, 2012-Present.
 Curriculum, learning objectives and expectations for each of the 6 ACGME core
competencies for 12 clinical rotations between two major hospitals, a research elective, and an
international experience available to all fellows for the HCMC Fellowship Training Program
in Cardiovascular Disease, 2011-Present.
 Core curriculum for HCMC Training Program in Cardiovascular Disease involving 1 month
of boot camp directed toward incoming fellows and a 40 week program divided into 4 major
educational themes involving 10 lectures each: ischemic heart disease, heart failure,
electrophysiology, and valvular/congenital heart disease, 2011-Present.
 Nuclear Cardiology curriculum, learning objectives and expectations for each of the 6
ACGME core competencies for the Cardiology Fellowship rotation in Nuclear Cardiology for
the University of Minnesota, 2002-2007.
 Web-based learning activity for interpretation of SPECT images "MIBI of the Month,”
University of Minnesota Cardiology Fellowship and Affiliate Faculty Members, 2001-2005.
Collaborative Efforts and Activities
 Co-Chair, Interdepartmental Task Force for establishing improved relations with the Renal
Transplant Service, 2013-Present.
 Co-Chair, Interdepartmental Task Force for establishing improved relations between
Emergency Medicine and Cardiology, 2012-Present.
 Program Director of Fellowship Training Program in Cardiovascular Disease coordinating
educational activities between two primary sites, Hennepin County Medical Center and
Abbott Northwestern Hospital, 2011-Present.
6  Steering Committee Member, NHLBI Heart Failure Clinical Trials Network, 2006-2012.
 Minnesota Heart Failure Consortium Advisory Board Member, 2002-Present.
 Member, Hennepin Faculty Associates (HFA) Board of Directors representing the Department
of Medicine, 2000-2003 and 2011-2012.
Faculty Development Activities Regarding Teaching
 Annual attendance at "educating the educators" session for program directors in Fellowship
training programs for cardiovascular disease, American College of Cardiology annual
scientific sessions, 2011-Present.
 Organized, facilitated and educated faculty from Hennepin County Medical Center and
Abbott Northwestern’s combined cardiology fellowship program during semiannual meetings
related to the evaluation of the cardiology fellows, 2011-Present.
 Chair, Clinical Competency Committee and Program Evaluation Committee for the
Fellowship training program and cardiovascular disease, 2011-Present.
Continuing Medical Education (invited CME lectures)
1. “Hot Topics from the American College of Cardiology (ACC) 2014,” Medicine Grand
Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, April 24, 2014.
2. “Effect of heart failure treatment strategies on development of cardiorenal syndrome" 63rd
annual scientific sessions of the American College of Cardiology, Washington DC, 2014.
3. "Rule of ultrafiltration in acute decompensated heart failure", joint symposium of the German
cardiac Society and Thai Heart Association and the American College of Cardiology, 63rd
annual scientific sessions of the American College of Cardiology, Washington DC, 2014.
4. “Heart Failure Trials: The Year in Review,” CARRESS-HF 17th Annual Scientific Meeting,
Heart Failure Society of America, Orlando, Florida, September 23, 2013.
5. “Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome–The Creation of
a Comparative Effectiveness Trial,” Medicine Grand Rounds, Hennepin County Medical
Center, Minneapolis, Minnesota, December 6, 2012.
6. “Cardiorenal Syndrome: CARRESS HF Trial Results and Implications,” Heart Failure 2012:
The Update, Minnesota Heart Failure Consortium, Edina, Minnesota, December 1, 2012.
7. “Advantages and Pitfalls of Ultrafiltration Therapy,” American College of Cardiology’s 61st
Annual Scientific Sessions and Expo, Chicago, Illinois, March 25, 2012.
8. “Heart Failure and Renal Failure,” Heart Failure 2011: The Update, 9th Annual Session of the
Minnesota Heart Failure Consortium, Minneapolis, Minnesota, October 29, 2011.
9. “Hemoconcentration with Ultrafiltration: Good or Bad?” 15th Annual Scientific Meeting,
Heart Failure Society of America, Boston, Massachusetts, September 19, 2011.
10. “NHLBI Heart Failure Clinical Trials Network–Introduction to Selected Ongoing Trials at
Hennepin County Medical Center,” Geriatrics Grand Rounds, Hennepin County Medical
Center, Minneapolis, Minnesota, August 9, 2011.
11. “Ultrafiltration: How, In Whom, and When to Do It?” Bakken Symposium 2010: Heart
Failure, University of Minnesota, Minneapolis, Minnesota, December 6, 2010.
12. “Should All Patients with Decompensated Heart Failure and Volume Overload Receive
Ultrafiltration?” Debate, Pro: Bart BA, Con: Walsh M. Heart Failure 2009: The Update, 7th
Annual Session of the Minnesota Heart Failure Consortium, Minneapolis, Minnesota,
November 7, 2009.
7 13. “Wanted: Dead or Alive; Myocardial Viability Testing,” Medicine Grand Rounds, Hennepin
County Medical Center, Minneapolis, Minnesota, December 11, 2008.
14. “Changes in Renal Function during Heart Failure Therapy: What is the Kidney Trying to Tell
Us?” 30th Annual Cardiovascular Conference, HealthPartners, Saint Paul, Minnesota,
December 4, 2008.
15. “Cardiorenal Syndrome,” Grand Rounds, Minneapolis Heart Institute, Minneapolis,
Minnesota, November 24, 2008.
16. “Cardiorenal Syndrome,” Grand Rounds, Minneapolis Veterans Medical Center,
Minneapolis, Minnesota, November 21, 2008.
17. “Ultrafiltration for Heart Failure: Mechanisms and Benefits,” 29th Annual Cardiovascular
Conference, HealthPartners, Saint Paul, Minnesota, 2008.
18. “Management of Acute Fluid Overload: Diuretics vs. Aquaphoresis,” Transcatheter
Cardiovascular Therapeutics (TCT) Meeting, Washington, DC, 2007.
19. “Ultrafiltration Benefits and Mechanisms,” Heart Failure Society of America, 11th Annual
Scientific Meeting, Washington, DC, 2007.
20. “Heart Failure for the Consultant Cardiologist: 2007 Update,” Session Co-chair, 56th Annual
Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 6,
2007.
21. “Managing CHF: Staying beyond the Hospital Walls,” Facilitator, Heart Center Conference,
Roundtable Discussion, Durham, North Carolina, 1995.
22. “The Cardiologist’s Role in Heart Failure Stages A-D.” CME Program for Minnesota
Chapter of the American College of Cardiology Annual Meeting, Minneapolis, Minnesota,
2006.
23. “Do All Patients with an EF <35% Need an ICD Device?” Debate Speaker, Pro: Alan Bank,
Con: Bart BA, Heart Failure 2006: The Update, Bloomington, Minnesota, 2006.
24. “Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Medicine Grand
Rounds, University of Illinois, Chicago, Illinois, 2006.
25. “Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Medicine Grand
Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, 2006.
26. “Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Grand Rounds,
Veterans Administration Medical Center, Minneapolis, Minnesota, 2006.
27. External Counterpulsation Therapy for Ischemic Heart Disease,” Medicine Grand Rounds,
Hennepin County Medical Center, Minneapolis, Minnesota, 2005.
28. “Nuclear Stress Testing in Clinical Decision Making,” Internal Medicine Grand Rounds,
University of Minnesota, Minneapolis, Minnesota, 2005.
29. “Ultrafiltration in the Postoperative and Congestive Heart Failure Patients,"
Cardiology/Surgery Conference, United Hospital, Saint Paul, Minnesota, 2005.
30. “Assessment of Myocardial Viability,” Health Partners 28th Annual Cardiovascular
Conference, Saint Paul, Minnesota, 2005.
31. “Meet the Thought Leaders and Industry Experts on EECP Therapy: A Noninvasive Therapy
for Heart Failure and Angina Pectoris," Meet the Experts, American College of Cardiology,
Satellite Symposia, Orlando, Florida, 2005.
32. “Does this Patient with Nonischemic Cardiomyopathy Need a Defibrillator?" Cardiology
Conference, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis,
Minnesota, 2004.
8 33. “Should this Patient get a Defibrillator: Controversies in Cardiology," Scientific and
Business Meeting, American College of Cardiology-Minnesota Chapter, Minneapolis,
Minnesota, 2004.
34. “Setting Up and Running of Stress Lab in Primary Care,” 5th Annual Lillehei Symposium,
University of Minnesota, Minneapolis, Minnesota, 2004.
35. “Stress Testing Basics: Nuclear Stress Tests,” 5th Annual Lillehei Symposium, University of
Minnesota, Minneapolis, Minnesota, 2004.
36. “Therapeutic Ultrafiltration for the Management of Fluid Overload: Current and Future
Role–The RAPID CHF Study,” Satellite Symposium, Heart Failure Society of America, Las
Vegas, Nevada, 2003.
37. “Myocardial Profusion Imaging: Update and Prognostic Implications,” Grand Rounds,
University of Minnesota, Minneapolis, Minnesota, 2000.
38. “Angiotensin Receptor Blockers: Mechanisms and New Directions,” Grand Rounds,
Veterans Administration Medical Center, Minneapolis, Minnesota, 1998.
39. “Nuclear Cardiac Imaging,” Medicine Grand Rounds, Hennepin County Medical Center,
Minneapolis, Minnesota, 1997.
40. “Management of Heart Failure,” Panelist, 15th Edward S. Orgain Cardiovascular Symposium,
Durham, North Carolina, 1996.
d. Teaching Effectiveness
New Innovations RMS Evaluations—HCMC-IM-CARD Co, Fellow Evaluation Summary for
time period 7/1/2006 to 6/30/2014
(Evaluation Scale: 5=high, 1=low)
Date Topic Evaluation # of Scores Evaluations 7/1/2011‐ Patient care – Supervises and provides compassionate, 4.50 6 6/30/2012 appropriate and effective patient care in all settings 7/1/2011‐ Medical Knowledge – Current with recent advances and 5.00 6 6/30/2012 demonstrates knowledge of current clinical guidelines 4.50 6 7/1/2011‐ Practice‐Based Learning and Improvement – Investigates 6/30/2012 and evaluates patient care appraisal and assimilation of scientific evidence and advances 7/1/2011‐ Systems Based Practice – Insures timely and continuous 5.00 6 6/30/2012 care, demonstrates awareness of and responsiveness 7/1/2011‐ Interpersonal and Communication Skills – Demonstrates 4.50 6 6/30/2012 skills with patients, residents, patient’s care team and hospital staff 7/1/2011‐ Professionalism – Projects positive image 4.50 6 6/30/2012 7/1/2011‐ Teaching‐appropriate guidance and feedback 4.50 6 6/30/2012 7/1/2011‐ Availability – Prompt, spent enough time on rounds, 4.50 6 6/30/2012 focused 7/1/2011‐ Availability – Reviewed expectations, provided feedback, 4.50 6 6/30/2012 give positive reinforcement 9 New Innovations RMS Evaluations—HCMC-IM-BLUE 1; HCMC-IM BLUE2; HCMC-IM-CARD
CON, Resident Evaluation Summary for time period 7/1/2006-6/30/2014
(Evaluation Scales: 5=high. 1=low, or 3=high, 1=low)
Date Topic Evaluation # of Scores Evaluations 7/1/2006‐
Communication with residents and primary team (3‐1) 89 6/30/2014 2.81 7/1/2006‐
Rounding & Teaching (3‐1) 89 6/30/2014 2.92 7/1/2006‐
Overall (5‐1) 89 6/30/2014 4.83 7/1/2006‐
Patient Care‐ provides compassionate, appropriate and (5‐1) 89 6/30/2014 effective patient care 4.60 7/1/2006‐
Medical Knowledge‐Stays current with medical (5‐1) 89 6/30/2014 advances and demonstrates knowledge of current 4.63 clinical guidelines 7/1/2006‐
Practice‐Based Learning and Improvement‐investigates (5‐1) 89 6/30/2014 and evaluates their own patient care 4.54 7/1/2006‐
Systems Based Practice‐Insures timely and continuous (5‐1) 89 6/30/2014 care of patients at all times 4.56 (5‐1) 89 7/1/2006‐
Interpersonal and Communication Skills‐demonstrates 4.54 6/30/2014 communication skills with patients, families, fellow providers, referring physicians, residents etc. (5‐1) 89 7/1/2006‐
Professionalism‐respectful of residents, staff and 4.65 6/30/2014 patients regardless of age, gender, religious or cultural difference 7/1/2006‐
Teaching‐provides appropriate guidance and feedback (5‐1) 89 6/30/2014 in patient management 4.61 7/1/2006‐
Availability‐prompt, adhered to rounds schedule, kept (5‐1) 89 6/30/2014 interruptions to minimum, appeared unhurried, focused 4.52 7/1/2006‐
Availability – Reviewed expectations, provided (5‐1) 89 6/30/2014 feedback, give positive reinforcement 4.38 7/1/2006‐
Patient Care‐ provides compassionate, appropriate and (5‐1) 89 6/30/2014 effective patient care 4.61 7/1/2006‐
Medical Knowledge‐Stays current with medical (5‐1) 89 6/30/2014 advances and demonstrates knowledge of current 4.66 clinical guidelines 7/1/2006‐
Practice‐Based Learning and Improvement‐investigates (5‐1) 89 6/30/2014 and evaluates their own patient care 4.75 7/1/2006‐
Systems Based Practice‐Insures timely and continuous (5‐1) 89 6/30/2014 care of patients at all times 4.75 10 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 7/1/2006‐
6/30/2014 Interpersonal and Communication Skills‐demonstrates communication skills with patients, families, fellow providers, referring physicians, residents etc. Professionalism‐respectful of residents, staff and patients regardless of age, gender, religious or cultural difference Teaching‐provides appropriate guidance and feedback in patient management Availability‐prompt, adhered to rounds schedule, kept interruptions to minimum, appeared unhurried, focused Overall Availability‐prompt, adhered to rounds schedule, kept interruptions to minimum, appeared unhurried, focused Availability – Reviewed expectations, provided feedback, give positive reinforcement Systems Based Practice‐Insures timely and continuous care of patients at all times Practice‐Based Learning and Improvement‐investigates and evaluates their own patient care Teaching‐provides appropriate guidance and feedback in patient management Medical Knowledge‐Stays current with medical advances and demonstrates knowledge of current clinical guidelines Interpersonal and Communication Skills‐demonstrates communication skills with patients, families, fellow providers, referring physicians, residents etc. Professionalism‐respectful of residents, staff and patients regardless of age, gender, religious or cultural difference Teaching‐provides appropriate guidance and feedback in patient management Medical Knowledge‐Stays current with medical advances and demonstrates knowledge of current clinical guidelines Patient Care‐ provides compassionate, appropriate and effective patient care Overall –evaluation of faculty Overall – rate your learning experience 11 (5‐1) 4.57 89 (5‐1) 4.66 89 (5‐1) 4.52 (5‐1) 4.59 (5‐1) 4.46 (5‐1) 4.65 (5‐1) 4.53 (5‐1) 4.55 (5‐1) 4.60 (5‐1) 4.69 (5‐1) 4.77 89 89 89 89 89 89 89 89 89 (5‐1) 4.57 89 (5‐1) 4.66 89 (5‐1) 4.69 (5‐1) 4.77 89 (5‐1) 4.76 (5‐1) 4.69 (5‐1) 4.39 89 89 89 89 Evaluator Comments: 
















Efficient at both patient care and teaching. Very approachable and goes out of his way to teach. AND it’s HIGH‐YIELD learning!! Excellent teacher – makes points to patient problems and articulated in a very clear manner. Thank you for taking the time to do extra teaching on a slow week. This rotation is top 3 in the hospital. Fun to work with. I feel like I learned something new every day. Dr. Bart is good at including the whole team in discussions on our patients during rounds. Really great working with Dr. Bart. He is very patient and thorough and teaches effectively. Dr. Bart is really an outstanding teacher. He is patient during resident presentations, elicits our care plan, and expands on our plan to provide teaching points on each individual patient. It’s my pleasure working with Dr. Bart. He is a great teacher and very collegial with residents. Looking forward to work with him again. Dr. Bart allowed residents to formulate plan, took time to explain the reasoning behind the recommendations, also he was focused on case based teaching which made the whole experience invaluable! Very knowledgeable, dedicated, and pleasant. Great week, one of the best teachers I have had. The only criticism that I would give is to make sure and let the resident and/or student make their assessment and plan known before jumping in. For confident students and residents, it doesn’t matter much, but for others it is important that you not only let them, but make them have an assessment and plan before outlining THE plan. Good teaching points, took his time with questions, helpful in physical exam skills. Dr. Bart is extremely knowledgeable in his area, up to date with recent literature, and teaches very well. He found teaching points in every case we saw. Outstanding cardiology faculty to work with. Very knowledgeable in current guidelines and most relevant trial results. Took time to teach cardiac physiology relevant to our cases. Served as a good role model in compassionate patient care at the bedside. Overall, an outstanding clinician and instructor. Dr. Bart is a superb teacher. His clinical acumen and extensive knowledge, along with high expectations and a Socratic teaching method, make for an excellent clinical experience as a resident. It is a pleasure to work with him. It is great to work with Dr. Bart. He teaches using a Socratic method that engages and requires independent thought. He shows patients, residents and students respect and is a very effective teacher‐clinician. Dr. Bart provided excellent teaching on rounds and was very good about prompting the resident about what the diagnosis and treatment plan was instead of just telling us what he felt we should do. He is thoughtful and compassionate. I feel I learned a lot working with him. 12 











Dr. Bart is such a great attending to work with, fun and professional. I always look forward to working cardiology. Dr. Bart once again taught me so much about cards. I am continuously humbled by the amount of learning in medicine and he highlights and encourages that thirst for knowledge and human betterment in us. Great teaching! Dr. Bart is a good teacher. I appreciated his impromptu lectures (white∙board talks) on various topics. Dr. Bart is a great teacher and clinician. He is always prompt and efficient and respectful of patients but also of residents and other staff. He is also great example of someone who practices medicine as an art. What struck me most while working with Dr. Bart was the amount of information we learned with each patient. Each patient cared for on the consult team is a gateway to education, and as a resident the value of that cannot be underestimated. He, and all of his colleagues in the cardiology department, are among those that make this a residency of the highest quality. Dr. Bart was very professional and helpful in sorting out consults. Very enjoyable to work with. It was a good learning experience with Dr. Bart. A model academic physician never hurried despite busy service. Really appreciate that Dr. Bart took the time to teach when things weren't as busy. An outstanding physician, cardiologist and teacher. I had the opportunity to learn from him three years in a row on cardiology and each year learned some more. He is an asset to the service. Thanks for the teaching. Efficient, great communication with consult team, treatment teams, patients and families. Great role model, encouraged residents to dig deeper and come up with plans, gently nudged them towards appropriate answer. Brad is fantastic, l have known him for 5 years and he has grown to be head of the CV Diseases Division and now Program Director of the Cardiology Program at HCMC/ANW without losing his collegial approach with staff and residents. It is commendable that in the midst of interview: season he was able to manage the busy Cardiology Consult Service in an impeccable way. 13 University of Minnesota Student Performance Analysis Report-Internal Medicine Clerkships
Evaluation Summary for time period 1/1/1990-06/30/2014
Date Topic Evaluation Criteria Evaluation Scores (percentage) # of Evaluations # of Evaluations 1/1/1990‐
Overall Teaching Skill 06/30/2014 Outstanding 100% 2 1/1/1990‐
Organization for Teaching 06/30/2014 setting clear expectations. Outstanding 100% 2 1/1/1990‐
Communication of knowledge 06/30/2014 in presentations and in articulation of clinical reasoning process. Outstanding 100% 2 1/1/1990‐
Stimulation of Problem 06/30/2014 Solving asking effective questions. 1/1/1990‐
Supervision of Clinical Work 06/30/2014 direct supervision and observation of clinical work. Outstanding 100% 2 Outstanding 100% 2 1/1/1990‐
Appropriate Balance Allowed 06/30/2014 provision of an appropriate balance between responsibility and supervision. 1/1/1990‐
Feedback Effectiveness 06/30/2014 clear, specific, timely, constructive, ongoing. Outstanding 100% 2 Outstanding 100% 2 1/1/1990‐
Relationships with Students 06/30/2014 supportive, patient, empathetic, approachable, respectful, courteous, punctual, accessible for help, enthusiasm for teaching 1/1/1990‐
Role Model 06/30/2014 knowledge and competence as a physician, professionalism, relationship with patients and families. Outstanding 100% 2 Outstanding 100% 2 14 Group Comments: Strengths. Teaching Strengths 

Took a great deal of time to teach on rounds in the morning in general and paid the students a lot of
attention in particular. I like his style of teaching informally on rounds in the morning.
The best approach to teaching I encountered on this rotation. Excellent job of describing
expectations at the beginning of his term and allowing students to initiate all the patient planning.
Cardiology Pathophysiology Course, University of Minnesota, Cardiovascular Fellowship
Course comments, November 2009
Comments






Very good instructor.
Fantastic!
Best instructor I’ve had so far!
Incredibly clear instruction. Really, really great pace and very helpful explanations. If we didn’t
understand, he would take us back a step, walk us through so we were all on the same page and could
learn the related material.
Dr. Bart is one of the best instructors I have ever had. He taught the pathophysiology of the heart in a
way that was clear and simple and thorough. His small group should be a model for the rest.
Dr. Bart was an amazing small group leader. I’m sorry that I only got to attend his group once.
Teaching /Instructional/Educations Activity
Clinical Nephrology Conference at HCMC for Nephrology faculty, fellows, residents and
medical students.
Date Topic Evaluation Evaluation # of Critique Score Evaluations Excellent Good Depth
of
coverage
1/9/2009 Renal Denervation
17
2
19
Quality of presentation
for Hypertension
17
2
Impact on patient care
14
5
Audiovisuals
17
2
How well did lecture meet objectives
18
1
Group Comments






Very interesting, thank you.
Awesome presentation, very interesting.
Excellent conference.
Excellent study, needs to come back yearly to follow the results of the study.
Fantastic, very interesting! Thank you for coming and sharing with us.
Early beneficial effects are considerable, interesting, will be interesting to see long term results.
15 16 Honors/Awards Received for Teaching Effectiveness
University of Minnesota
Teacher of the Year, University of Minnesota Cardiovascular Fellows,
Minneapolis, Minnesota
19 2006-2007
Bradley A. Bart, M.D., F.A.C.C.
6. RESEARCH AND SCHOLARSHIP
a. Percent effort 15%
b. Narrative Summary
I am a clinical cardiologist with an interest in heart failure. My colleague Steven Goldsmith and I
developed a regional network of academic and non-academic institutions to facilitate
collaboration on heart failure research. This network, the Minnesota Heart Failure Consortium,
combined the talents and resources of most of the major heart failure research organizations in
Minnesota; IRB approval, contracting, monitoring, protocol development and communications
were streamlined to enhance our ability to efficiently perform industry sponsored trials as well as
investigator initiated studies.
The design and success of the Minnesota Heart Failure Consortium led to our successful
application to the National Heart, Lung, and Blood Institute's Heart Failure Clinical Trials
Network in 2006, one of 9 Regional Clinical Centers (RCCs) across the nation. The purpose of
the NHLBI Heart Failure Network was to provide a mechanism to expedite clinical research that
evaluates strategies to diagnose, manage and treat all forms of heart failure and the Minnesota
RCC played a significant leadership role in the development of protocols and enrollment of
patients. The Minnesota RCC was recognized by the NHLBI Heart Failure Network in 2010
with an award for excellence for achieving the best overall combination of enrollment and
endpoint completion. I served on the national steering committee and as Principal or Coprincipal investigator for the Minnesota RCC sites for these trials. The first round of trials
designed and executed by the NHLBI Heart Failure Network have been published in top-tier
journals and have influenced the practice of medicine and the approach to treating patients with
heart failure. These studies include: DOSE (NEJM 2011), CARRESS HF (NEJM 2012), RELAX
(JAMA 2013), ROSE (JAMA 2013), and EXACT (manuscript in preparation).
I have been interested in ultrafiltration as an alternative to loop diuretics for the treatment of
congestion in heart failure since 2002. At that time, I designed and coordinated the first
randomized controlled comparison of ultrafiltration versus IV diuretics in patients hospitalized
with acute decompensated heart failure - the RAPID trial (JACC 2005). This was a successful
feasibility study demonstrating that ultrafiltration could be safely performed in a multicenter
study and provided valuable information needed to plan the much larger UNLOAD study (JACC
2007). I helped design the UNLOAD study, was on the national steering committee, and was the
site PI at HCMC. UNLOAD stimulated national interest in ultrafiltration for acute heart failure.I
wrote the protocol and served as the national PI for the CARRESS HF trial, a randomized
controlled trial of ultrafiltration vs. stepped pharmacologic care in patients with acute heart
failure and cardiorenal syndrome conducted by the NHLBI Heart Failure Network. CARRESS
HF (NEJM 2012) has had a significant impact on the current use of ultrafiltration and has
contributed significantly to ongoing debate regarding the indications and prescription of
ultrafiltration in acute heart failure. Currently, I am on the national steering committee and am
the site PI at HCMC for the AVOID trial - a trial of similar design to UNLOAD, but powered for
heart failure events at 90 days as a primary endpoint (NCT01474200). As a result of this body of
1
work, ultrafiltration has been incorporated into the guidelines for the treatment of acute heart
failure by the Heart Failure Society of America, the American College of Cardiology
Foundation/American Heart Association, the Canadian Cardiovascular Society, the International
Society of Heart and Lung Transplantation, and the European Society of Cardiology.
I am recognized nationally and internationally as an expert in the area of ultrafiltration and other
acute decongestive strategies for heart failure and have been invited to speak at the annual
scientific sessions of the American College of Cardiology, the American Heart Association, and
the Heart Failure Society of America. I have been invited to write book chapters, editorials and
perspective papers on ultrafiltration for the American Heart Journal, Cardiology Review,
Congestive Heart Failure, the Journal of Cardiac Failure, the Journal of the American College of
Cardiology, and Circulation Heart Failure.
As a clinical trialist, I have also been the site PI or Co-PI on a number of other clinical trials
dealing with heart failure. These trials have contributed considerably to our current
understanding of specific interventions for heart failure and include: OPTIME HF (milrinone);
REVIVE (levosimendan); VMAC, TRUE HF, and CD-NP (trials of natriuretic peptides
including nesiritide, uleritide, and cenderitide in acute heart failure); EVEREST (tolvaptan) and a
number of other trials of AVP antagonists; PROTECT (rolofylline); BEST (bucindolol), PRAISE
II (amlodipine), A-HeFT (hydralazine/isosorbide mononitrate), SPICE and CHARM
(candesartan).
New devices often have great potential for clinical benefit, but research is needed to identify the
proper patient population, indication, and combination with other standard therapies. I am
interested in new technologies and how they can be used effectively in the clinical setting. I was
the site PI for the first human application of renal denervation for the treatment of hypertension
in North America. These first few procedures, performed in the cardiac catheterization
laboratory at Hennepin County Medical Center, were instrumental in developing the protocol
and techniques that would ultimately be used in the SIMPLICITY II and III studies. Another
first in man experience based at HCMC in which I was the site PI was phrenic nerve stimulation
as a means of treating central sleep apnea. These studies were critical in establishing proof of
concept and developing pacing algorithms that were later incorporated into a fully implantible
device that is currently under investigation. I was the site PI for the PEECH study examining the
effectiveness and safety of enhanced external counterpulsation (EECP) in chronic heart failure
and served on the Steering Committee and Writing Group for the International EECP patient
registry which published papers examining the effect of EECP on peripheral arterial disease,
erectile dysfunction, and severe 3 vessel coronary artery disease. I was invited to write a book
chapter on the role of EECP in the management of chronic coronary artery disease.
I have maintained an interest in nuclear cardiac imaging and have been the site PI for a number
of related clinical trials. These trials have included studies of new vasodilator stress agents
(regadenoson and other A2 selective adenosine agonists); ischemia markers such as iodofitic acid
I123; imaging agents such as tetrofosmin; and an investigator initiated study comparing the
accuracy of dobutamine stress echocardiography, dobutamine SPECT, and adenosine SPECT in
patients with ESRD.
2
Other clinical trials I have participated in as site PI or Co-PI include studies of apixaban and
otamixaban, new anticoagulants for acute coronary syndromes; growth factors for chronic
ischemic heart disease (VEGF and FGF), carotid artery stiffness in patients at risk for CAD,
antidepressants in post MI patients (SADHART), and the combination of PDE-5 inhibitors and
IV nitroglycerin in patients with chronic coronary artery disease.
My scholarly interests have led to publications and/or national presentations in the areas of
underuse of ACE inhibitors (Am Journal of Cardiology 1997); ischemic versus non-ischemic
cardiomyopathy (JACC 1997); the effects of cocaine on the formation of coronary artery
aneurisms (Circulation 2005); long term survival in patients with chronic coronary artery disease
(European Heart Journal 2013); and rare complications following septal reduction surgery in
hypertrophic cardiomyopathy (Echocardiography 2013).
c. Grants and contract support, peer-reviewed publications, non-peer reviewed
publications, book chapters, scientific/professional presentations and abstracts
Grants and Contracts
Current Funding: Direct involvement as PI or Co-PI in 6 industry-sponsored clinical trials
totaling more than $1.7 million for direct and indirect costs.
Principal Investigator
Current
1. Longitudinal Assessment of Cardiovascular and Renal Health in Patients with HepatitisC (CARE-Hep C) Protocol Version/ Date: Version 3.0, Bristol‐Myers Squibb, $68,250,
Principal Investigator, February 2014-January 2015. (Direct cost, total project period)
2. Renal and neural hormonal effects of tolvaptan and B. type natruretic peptide in patients
with congestive heart failure HSR#13-3708, $132,200, Principal Investigator, August
2013-July 2014. (Direct cost, total project period)
3. The Targeting Acute Congestion with Tolvaptan In Congestive Heart Failure
StudyTACTICS-HF, Principal Investigator, $41,000, December 2012-November 2013.
(Direct cost, Total project period)
4. A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess
Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared
to Regadenoson Alone For Myocardial Perfusion Imaging (MPI) Using Single Photon
Emission Computed Tomography (SPECT) Protocol for Phase 3b Study of CVT3146
(Regadenoson) EXERRT – EXErcise to Regadenoson in Recovery Trial, $1,264,000,
Principal Investigator, September 2012-September 2014. (Direct cost, total project
period)
5. Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure,
GAMBRO, #1494, Principal Investigator, July 2012-Present. (Annual project period)
3
Past
1. Renal Optimization Strategies Evaluation in Acute Heart Failure: ROSE-AHF, Heart
Failure Network, Principal Investigator, March 2011-Present. (Annual project period)
2. Randomized, Double-blind, TD Trial to Compare the Efficacy of Otamixaban with
Unfractionated Heparin + Eptifibatide in Patients with Unstable Angina/Non ST Segment
Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy,
Sanofi, 04629-XRP0673A, Principal Investigator, July 2010-July 2013. (Total project
period)
3. Hyponatremia Registry, Otsuka, #04645, Principal Investigator, December 2010December 2012. (Total project period)
4. Renal Denervation in Patients with Refractory Hypertension Pilot Study, Ardian, HSR
# 08 2915, Principal Investigator, May 2009-2011. (Total project period)
5. Renal Denervation in End Stage Renal Disease Patients with Refractory Hypertension,
Pilot Study, Ardian, HSR # 08 2916, Principal Investigator, May 2009-2011. (Total
project period)
6. Comparative Effects of Conivaptan and Loop Diuretics on Plasma Neurohormones and
Systemic and Renal Hemodynamics in Subjects with Chronic Heart Failure-CONVERT,
Astelles, HSR # 09-3035, Principal Investigator, May 2009-2010. (Total project period)
7. Phase 4, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety
and Tolerance of Regadenoson in Subjects with Renal Impairment-Lexiscan, Astellas,
HSR #093089, Principal Investigator, August 2009-2010. (Total project period)
8. Appraise II: Apixaban for Prevention of Acute Ischemic Events – 2 A Phase 3,
Randomized, Double-blind Evaluation of the Safety and Efficacy of Apixaban In
Subjects with a Recent Acute Coronary Syndrome, Bristol-Myers Squibb Research and
Development, HSR # 09-3050, Principal Investigator, May 2009-2011. (Total project
period)
9. Placebo-controlled, Randomized Study of the Selective A1 Adenosine Receptor
Antagonist KW-3902 for Patients Hospitalized with Acute HF and Volume Overload to
Assess Treatment Effect on Congestion and Renal Function (PROTECT), Merck,
HSR#06-2693, Principal Investigator, 2006-2009. (Total project period)
10. Feasibility Study to Determine the Effects of Synchronized Phrenic Nerve Stimulation in
Patients with Periodic Breathing, Cardiac Concepts, Inc., HSR#07-2841, Principal
Investigator, $155,000, September 2007. (Direct cost, total project period)
11. Cardiorenal Rescue Study in Acute Decompensated Heart Failure-CARRESS, NIH HF
Network, HSR#07-2862, Principal Investigator, April 2007. (Total project period)
4
12. Open-Label, Phase 2 Study of the Safety and Efficacy of -Methyl-p-[123l]-IodophenylPentadecanoic Acid (Iodofiltic Acid l 123) for Identification of Ischemic Myocardium
Using Single Photon Emission Computed Tomography (SPECT) in Adults with
Symptoms Consistent with Acute Coronary Syndrome (ACS), Molecular Insight
Pharmaceuticals, Inc., HSR#07-2829, Principal Investigator (Percent effort: 2%),
September 2007-September 2009. (Total project period)
13. Outpatient Ultrafiltration Therapy in Heart Failure – Pilot, CHF Solutions, Inc., HSR
#06-2642, Principal Investigator, (Percent effort: 2%), $11,036, May 2006. (Total project
period)
14. Phase 3, Parallel, Double-blind, Multicenter Trial to Examine Inducible Myocardial
Perfusion Abnormality Detection with BMS068645 and Adenosine Stress Single Photon
Emission Computer Tomography (SPECT) Compared to Coronary Angiography, BMS
Medical Imaging, HSR#05-2497, Principal Investigator, (Percent effort: 2%), $138,000,
2005. (Direct cost, total project period)
15. Randomized, Controlled Pilot Study: Induction of Mild Hypothermia in Resuscitated
Cardiac Arrest Patients Using Traditional Cooling Techniques versus the Medivance
Arctic Sun System, Medivance, HSR#04-2421, Principal Investigator, (Percent effort:
2%), $50,800, 2004. (Direct cost, total project period)
16. The UNLOAD Trial. Ultrafiltration versus IV Diuretics for Patients Hospitalized for
Acute Decompensated Congestive Heart Failure: A Prospective, Randomized Clinical
Trial, CHF Solutions, Inc., HSR# 04-2377, Principal Investigator, (Percent effort: 2%),
$52,500, 2004. (Direct cost, total project period)
17. Referral Bias in the Selection of Stress Echo and Myocardial Perfusion Imaging Studies,
Investigator initiated and funded, HSR#04-2370, Principal Investigator, (Percent effort:
2%), 2004. (Total project period)
18. Phase II, Open-label, Randomized, Dose-selection, Multicenter Crossover Trial of
BMS068645 in Subjects Undergoing Pharmacologic Stress Myocardial SPECT Imaging,
Bristol Meyers Squibb, HSR# 04-2351, Principal Investigator, (Percent effort: 2%),
$35,000, 2004. (Direct cost, total project period)
19. Non-invasive Measurement of Carotid Arterial Stiffness in Patients Admitted to a Short
Stay Coronary Unit Using the Stiffness Index , Investigator initiated and funded, HSR#
04-2309, Principal Investigator, (Percent effort: 2%), 2004. (Total project period)
20. Exercised SPECT Myocardial Perfusion Imaging in Patients Receiving Beta-blockers:
Impact of Adjuvant Adenosine Infusion on the Detection of Ischemia: BEAST-2,
Fujisawa, HSR# 03-2299, Principal Investigator, $12,500, 2004. (Direct cost, total
project period)
5
21. Study of Clinical Observations and Outcomes Following a Pharmacological Stress
SPECT Myocardial Perfusion Imaging Procedure (Protocol #K627-02-5001), King
Pharmaceuticals, #03-2166, Principal Investigator, February 2003-July 2003. (Total
project period)
22. Enhanced Eternal Counterpulsation (EECP) in Heart Failure: A Single-blind, Controlled,
Randomized Evaluation of Efficacy and Safety (PEECH), Vasomedical, #03-2210,
Principal Investigator, (Percent effort:4%), $35,000, 2003. (Direct cost, total project
period)
23. Randomized, Controlled Trial of Ultrafiltration for Decompensated Congestive Heart
Failure, CHF Solutions, HSR# 03-2184, Principal Investigator, Multicenter Study,
(Percent effort: 8%), $240,000, 2003. (Direct cost, total project period)
24. Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy versus
Placebo in the Short-term Treatment of Decompensated Chronic Heart Failure
(REVIVE), Orion Pharma, HSR# 02-1087, Principal Investigator, (Percent effort: 4%),
$78,150, 2002. (Direct cost, total project period)
25. Effect of Enhanced External Counterpulsation (EECP) on Heart Rate Variability in
Patients with Chronic Stable Angina, Vasomedical, HSR# 02-2059, (Percent effort: 2%),
$5,000, 2002. (Direct cost, total project period)
26. The International Enhanced External Counterpulsation (EECP) Patient Registry (IEPR2), Vasomedical, HSR# 02-2011, Principal Investigator, (Percent effort: 1%), 2002.
(Total project period)
27. Study of Clinical Observations and Outcomes Following a Pharmacological Stress
SPECT Myocardial Perfusion Imaging Procedure, King Pharmaceutical Research and
Development, Incorporated, HSR# 03-2166, Principal Investigator, (Percent effort: 2%),
$7,500, 2002. (Direct cost, total project period)
28. International EECP Patient Registry 2 Men’s Health Study, Vasomedical, HSR# 022058, Principal Investigator, (Percent effort: 1%), 2002. (Total project period)
29. Double-blind, Placebo-controlled, Randomized, Two-way Crossover Study to Investigate
the Highest Intravenous Dose of GTN That can Be Safely Administered in Men with
Coronary Artery Disease Around Peak Systemic Exposure of Sildenafil, as Well as
Safety and Tolerability of Intravenous GTN Given After a Single 100mg Dose of
Sildenafil, Pfizer, HSR# 01-1032, Principal Investigator, (Percent effort: 1%), 2001.
(Total project period)
30. P-Selectin Glycoprotein Ligand – LG Study, Wyeth-Ayerst Res, Principal Investigator,
2001. (Total project period)
6
31. Hennepin County Medical Center EEEP Patient Registry (HEPR), Investigator initiated
and funded, HSR# 01-1051, Principal Investigator, (Percent effort: 1%), 2001. (Total
project period)
32. The International Enhanced External Counterpulsation (EECP) Patient Registry (IEPR),
Vasomedical, HSR# 01-948, Principal Investigator, (Percent effort: 1%), 2001. (Total
project period)
33. Clinical Protocol for the Evaluation of the Cobalt Binding Test for Use as an Aid in the
Diagnosis of Ischemia, Ischemia Technologies, Incorporated, HSR# 01-1059, Principal
Investigator, (Percent effort: 2%), $45,000, 2001. (Direct cost, total project period)
34. Effect of Enhanced External Counterpulsation (EECP) on Heart Rate Variability and
Baroreflex Sensitivity in Cardiac Patients, Investigator initiated and funded, HSR# 01982, Principal Investigator, (Percent effort: 1%), 2001. (Total project period)
35. Omipatrilat Cardiovascular Treatment Assessment versus Enalapril (OCTAVE),
BristolMyers Squibb Davita, HSR# 00-911, Principal Investigator, (Percent effort: 2%),
2000. (Total project period)
36. Tc99m Gated SPECT Perfusion Imaging and Dobutamine Stress Echocardiography for
the Evaluation of CAD and Prognosis in Renal Failure Patients, Hennepin Faculty
Associates (HFA), HSR#99-749, Principal Investigator. 1999. (Total project period)
37. Tc99 Gated SPECT Perfusion Imaging and Dobutamine Stress Echocardiography for the
Evaluation of Coronary Artery Disease and Prognosis in Renal Failure Patients,
Minneapolis Medical Research Foundation (MMRF); DuPont Pharmaceuticals, HSR#
99-749, Principal Investigator, (Percent effort: 4%), $57,299 – MMRF; $7,500 – DuPont
Pharmaceuticals, 1999. (Direct cost, total project period)
38. Bracco Tc 99m Teboroxime Run-in Study: A Clinical Evaluation to Determine Optimal
Imaging Parameters for Tc-99m Teboroxime in Subjects with Coronary Artery Disease
and Subjects with no Evidence of Coronary Artery Disease, Bracco Diagnostics, #99795, Principal Investigator, (Percent effort: 2%), 1999. (Total project period)
39. Candesartan Cilexetil (Candesartan) in Heart Failure Assessment of Reduction in
Mortality and Morbidity (CHARM), AstraZeneca Pharmaceuticals, HSR# 99-699,
(Percent effort: 4%), $49,850, 1999. (Direct cost, total project period)
40. 12-week, Double-blind, Placebo-controlled, Multicenter Study of Oral YM087 to Assess
Functional Capacity in Patients with Class III Chronic Heart Failure, ParkeDavis/Warner-Lambert Company, #98-596, Principal Investigator, (Percent effort: 4%),
$28,000, 1998. (Direct cost, total project period)
41. Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of
Intravenous Milrinone Versus Placebo in Reducing the Number of Days of
7
Hospitalization in the 60 Days Following Entry into the Study for Treatment of Leftsided Heart Failure (OPTIME of CHF), Sanofi Pharmaceuticals through Duke Clinical
Research Institute, HSR# 97-464, Principal Investigator, (Percent effort: 2%), $15,000,
1997. (Direct cost, total project period)
42. Randomized, Double-blind, Placebo-controlled Trial of Sertraline (Zoloft) for Major
Depression after Acute Coronary Syndromes: Myocardial Infarction or Unstable Angina:
The SADHART Trial, Pfizer through Duke Clinical Research Foundation, #97-463,
Principal Investigator, (Percent effort: 4%), $36,407, 1997. (Direct cost, total project
period)
Co-Principal Investigator
Current
1. TRUE HF Phase III, multicenter, randomized, double-blind, placebo-controlled trial to
evaluate efficacy and safety ularitide intravenous infusion in patients suffering from acute
decompensated heart failure, $259,060, Co-Principal Investigator, March 2013–Present,
(Total cost, annual project period)
Past
1. Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients: EXACT-HF,
Heart Failure Network, Co-Principal Investigator, 2010-Present. (Total project period)
2. Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the
Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated
Heart Failure and Renal Insufficiency – TRIDENT, Biogen, HSR # 09-3038, CoPrincipal Investigator, June 2009-2010. (Total project period)
3. Multi-Center, Randomized, Placebo-controlled, Phase 2B Study Assessing the Safety and
Efficacy of Early Administration of Intravenous CD-NP Versus Placebo in the Treatment
of Patients with Acute Decompensated Heart Failure – CONDITION, Nile, HSR# 093026, Co-Principal Investigator, April 2009-2010. (Total project period)
4. Randomized, Double-blind, Placebo-controlled, Dose-ranging Pilot Study Evaluating the
Efficacy and Safety of YM087 in Patients with Decompensated Chronic Heart Failure,
Yamanouchi Pharma America, Inc., HSR# 02-2097, Co-Principal Investigator, (Percent
effort: 2%), 2003. (Total project period)
5. The African American Heart Failure Trial (A-HeFT) a Placebo-controlled Trial of BiDil
Added to Standard Therapy in African American Patients with Heart Failure and Substudy – Genetic Risk Assessment of Heart Failure in African Americans (GRAHF),
Nitromed, Inc., HSR# 01-1035, Co-Principal Investigator, (Percent effort: 2%), 2003.
(Total project period)
6. Multicenter, Randomized, Double-blind, Placebo-controlled Study of OPC-41061 to
Evaluate the Effects of OPC-41061 on the Acute and Chronic Outcomes of Patients
Hospitalized with Worsening Congestive Heart Failure, Acute and Chronic Therapeutic
Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV-CHF), Otsuka
8
America Pharmaceuticals, Inc., HSR# 00-926, Co-Principal Investigator, (Percent effort:
2%), 2001. (Total project period)
7. Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to
Evaluate the Efficacy and Safety of Ad.1 FGF-4 in Patients with Stable Angina, Berlex
Labs, Inc., #01-997, Co-Principal Investigator, (Percent effort: 2%), 2001. (Total project
period)
8. Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Hemodynamic
and Clinical Effects of Natrecor (nesiritide) Compared with Nitroglycerin Therapy for
Symptomatic Decompensated CHF, Scios, #99-769, Co-Principal Investigator, (Percent
effort: 2%), 2000. (Total project period)
9. Randomized, Double-blind Study to Compare the Effects of Carvedilol versus Placebo on
Left Ventricular Remodeling in Patients Post-myocardial Infarction (COVERT), Glaxo
Smith Kline, #98-634, Co-Principal Investigator, (Percent effort: 2%), 2000. (Total
project period)
10. Multicenter, Open-label, Dose-escalating Study of Intramyocardial Vascular Endothelial
Growth Factor 2 (VEGF 2) Gene Therapy in Refractory Patients with Stable Exertional
Angina who are no Candidates for Revascularization Procedures, Genetech, #99-682, CoPrincipal Investigator, (Percent effort: 2%), 1999. (Total project period)
11. Omapatrilat versus Enalapril Randomized Trial of Utility in Reducing Events
(OVERTURE), BristolMyers Squibb, #99-770, Co-Principal Investigator, (Percent effort:
2%), 1999. (Total project period)
12. Phase II, Double-blind, Placebo-controlled Study to Assess the Effect of Intracoronary
and Multiple Intravenous Administrations of rh VEGf on Exercise Tolerance in Adults
with Viable but Underperfused Myocardium (VIVA VEGf), Genentech, Co-Principal
Investigator, (Percent effort: 2%), 1997. (Total project period)
13. The Effect of Amlodipine on Regional Myocardial Blood Flow in Patients with Ischemic
Cardiomyopathy, Pfizer, Co-Principal Investigator, (Percent effort: 5%), $15,000, 1996.
(Direct cost, total project period)
14. The Effect of Amlodipine on Regional Myocardial Blood Flow using Dynamic Positron
Emission Tomography in Patients with Non-ischemic Cardiomyopathy, Pfizer, CoPrincipal Investigator for the PRAISE II sub-study, (Percent effort: 5%), $15,000, 1996.
(Direct cost, total project period)
Co-investigator
Past
1. CardioMems Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in
NYHA Class III Heart Failure Patients-CHAMPION, CardioMems, Co-Investigator, July
2007. (Total project period)
9
2. Phosphodiesterase-5 Inhibition to Improve Quality of Life and Exercise Capacity in
Diastolic Heart Failure – RELAX, NIH HF Network, HSR#07-2851, Co-Investigator,
April 2007. (Total project period)
3. Diuretic Optimization Strategies Evaluation in Acute Heart Failure-DOSE, NIH HF
Network, HSR#07-2852, Co-Investigator, April 2007. (Total project period)
4. NIH Heart Failure Network, NIH, #6099, Co-Investigator, (Percent effort: 20%),
$900,000, September, 2006 – September, 2011. (Direct cost, total project period)
5. Phase II, Multi-Center, Randomized, Double-blind, Flexible-dose Study of ZP120
Administered with IV Infusion as Add-On Therapy in Patients with Acute or Sub-Acute
Decompensated Chronic Heart Failure NYHA Class III-IV Treated with Furosemide
(Zealand), Zealand, HSR#06-2627, Co-Investigator, 2006-2007. (Total project period)
6. 12-week, Randomized, Open-label, 3-arm, Parallel-group Multicenter, Phase 111b Study
Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of
Atorvastatin 80 in Patients with Acute Coronary Syndromes (LUNAR), Astra/Zeneca,
HSR#06-2598, Co-Investigator, 2006-2007. (Total project period)
7. Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Longterm Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with
Worsening Congestive Heart Failure, Otsuka, #03-2271, Co-Investigator, (Percent effort:
1%), 2003. (Total project period)
8. Exploratory Study of Intravenously Administered YM 087 (CI-1025) to Assess Safety
and Efficacy in Patients with Acute Decompensation of Chronic Heart Failure, ParkeDavis/Warner-Lambert Company, #99-797, Co-Investigator, (Percent effort: 1%), 1997.
(Total project period)
Investigator
Past
1. Randomized, Double-blind, Multicenter Pilot Safety Study of the Addition of Ecadotril
50 to 400 mg BID or Placebo to the Background of Conventional Therapy in Patients
with Symptomatic Congestive Heart Failure, Bayer, #Bay y 7432, Investigator, (Percent
effort: 4%), 1996. (Total project period)
2. PRAISE II, Phase III trial of Amlodipine in Patients with Nonischemic Cardiomyopathy,
Pfizer, Investigator, (Percent effort: 2%), 1996. (Total project period)
3. BEST Phase III Trial of Bucindolol in Patients with CHF, US National Heart, Lung, and
Blood Institute; Department of Veterans Affairs Cooperative Studies Program; Incara
Pharmaceuticals (drugs), Investigator, (Percent effort: 2%), 1996. (Total project period)
10
Peer-reviewed publications
Citation Indices accessed May, 2014 by Google Scholar, Citations 2567; h-index 20; 10-index 25
1.
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR,
Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL,
O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM,
Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG,
McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald
E, Redfield MM; NHLBI Heart Failure Clinical Research Network.. Low-Dose
Dopamine or Low-Dose Nesiritide in Acute Heart Failure with Renal Dysfunction: The
ROSE Acute Heart Failure Randomized Trial. JAMA. 2013; 310(23):2533-2543.
doi:10.1001/jama.2013.282190.
Contribution: Developed protocol with Heart Failure Network Steering Committee, site
investigator, enrolled patients, assisted in review of data and analysis, assisted in review
and editing of manuscript.
Impact Factor: 29.978 in 2012; Sum of times cited: 13
2.
Schlaich MP, Bart BA, Hering D, Walton A, Marusic P, Mahfoud F, Bohm M, Lambert
EA, Krum H, Sobotka PA, Schmieder RE, Ika-Sari C, Eikelis N, Straznicky N, Lambert
GW, Esler MD. Feasibility of catheter-based renal nerve ablation and effects on
sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int
J Cardiol. 2013;168(3):2214-2220.
Contribution: Assisted in protocol development, site principal investigator, enrolled
patients, assisted in review of data and analysis, assisted in review and editing of
manuscript
Impact Factor: 5.509 in 2012; Sum of times cited: 29
3.
Chen HH, AbouEzzeddine OF, Anstrom KJ, Givertz MM, Bart BA, Felker GM,
Hernandez AF, Lee KL, Braunwald E, Redfield MM; Heart Failure Clinical Research
Network. Targeting the kidney in acute heart failure: can old drugs provide new benefit?
Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. Circ
Heart Fail. 2013;6(5):1087-1094.
Contribution: developed protocol with Heart Failure Network Steering Committee, site
investigator, enrolled patients, assisted in review of data and analysis, assisted in review
and editing of manuscript.
Impact Factor: 6.684 in 2012; Sum of times cited: 1
4.
Kalra A, Kohl LP, Asinger RW, Bachour FA, Van Camp JR, Ayenew W, Bart BA.
Aorto-right atrial fistula at aortotomy site following surgical myectomy.
Echocardiography. 2013;30(9):E300-301.
Contribution: Initially described the case and assisted with review and editing of
manuscript.
Impact Factor: 1.261 in 2012; Sum of times cited: 1
5.
Bart BA, Nelson SE. Eplerenone: another drug to add to the mix? J Am Coll Cardiol.
2013;62(17):1594-1595.
11
Contribution: Invited to write this editorial, assisted with review and editing of
manuscript.
Impact Factor: 14.086 in 2012; Sum of times cited: 1
6.
Henry TD, Satran D, Hodges JS, Johnson RK, Poulose AK, Campbell AR, Garberich RF,
Bart BA, et al. Long-term survival in patients with refractory angina. Eur Heart J.
Published online May 12, 2013; doi:10.1093/eurheartj/eht165.
Contribution: Patient recruitment and enrollment for participation in the registry,
assisted with review and editing of manuscript.
Impact Factor: 14.097 in 2012; Sum of times cited: 4
7.
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM,
Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO,
O'Connor CM, Felker GM, Goldsmith SR, Bart BA, et al. Effect of Phosphodiesterase-5
Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved
Ejection Fraction: A Randomized Clinical Trial (RELAX trial). JAMA.
2013;309(12):1268-1277.
Contribution: developed protocol with Heart Failure Network Steering Committee, site
investigator, enrolled patients, assisted in review of data and analysis, assisted in review
and editing of manuscript.
Impact Factor: 29.978 in 2012; Sum of times cited: 80
8.
Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure
with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-304
Contribution: Developed and wrote protocol with Heart Failure Network Steering
Committee, national principal investigator, enrolled patients, primary review of data and
analysis, wrote manuscript.
Impact Factor: 51.658 in 2012; Sum of times cited: 139
9.
Bart BA, Goldsmith SR, Lee KL, et al. Cardiorenal rescue study in acute decompensated
heart failure: Rationale and design of CARRESS-HF, for the heart failure clinical
research network. J Card Fail. 2012;18(3):176-182.
Contribution: Developed and wrote protocol with Heart Failure Network Steering
Committee, national principal investigator, wrote manuscript.
Impact Factor: 3.320 in 2012; Sum of times cited: 32
10.
Ponikowski P, Javaheri S, Michalkiewicz D, Bart B, et al. Transvenous phrenic nerve
stimulation for the treatment of central sleep apnoea in heart failure. Eur Heart J.
2012;33(7):889-894.
Contribution: Site principal investigator of this first-in-man device feasibility trial,
helped develop the study protocol, enrolled patients, oversaw procedure and testing,
assisted in editing of manuscript.
Impact Factor: 14.097 in 2012; Sum of times cited: 36
11.
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter
MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE,
12
Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, et al.
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med.
2011;364(9):797-805.
Contribution: Developed protocol with Heart Failure Network Steering Committee, site
investigator, enrolled patients, assisted in review of data and analysis, assisted in review
and editing of manuscript.
Impact Factor: 51.658 in 2012; Sum of times cited: 343
12.
Goldsmith SR, Sobotka PA, Bart B. The sympathorenal axis in hypertension and heart
failure. J Card Fail. 2010;16(5):369-373.
Contribution: developed concept, assisted in writing and editing of manuscript.
Impact Factor: 3.320 in 2012; Sum of times cited: 5
13.
Thakkar BV, Hirsch AT, Satran D, Bart BA, et al. The efficacy and safety of enhanced
external counterpulsation in patients with peripheral arterial disease. Vasc Med.
2010;15(1):15-20.
Contribution: Patient recruitment and enrollment for participation in the registry,
assisted with review and editing of manuscript.
Impact Factor: 1.617 in 2012; Sum of times cited: 5
14.
Shroff GR, Cen YY, Duprez DA, Bart BA. Relationship between carotid artery stiffness
index, BNP and high-sensitivity CRP. J Hum Hypertens. 2009;23(12):783-787.
Contribution: Resident research advisor, assisted in development of protocol, review and
analysis of data, review and editing of manuscript.
Impact Factor: 2.818 in 2012; Sum of times cited: 5
15.
Bart BA. reatment of congestion in congestive heart failure: ultrafiltration is the only
rational initial treatment of volume overload in decompensated heart failure. Circ Heart
Fail. 2009;2(5):499-504.
Contribution: Invited perspective piece, wrote manuscript.
Impact Factor: 6.684 in 2012; Sum of times cited: 32
16.
Bart BA, Cen YY, Hendel RC, et al. Comparison of dobutamine stress
echocardiography, dobutamine SPECT, and adenosine SPECT myocardial perfusion
imaging in patients with end-stage renal disease. J Nucl Cardiol. 2009;16(4):507-515.
Contribution: Principal investigator of this investigator-initiated project, independently
developed the concept and study design, wrote study protocol, responsible for conduct of
study, data acquisition, analysis and manuscript preparation.
Impact Factor: 2.847 in 2012; Sum of times cited: 7
17.
Thorsgard M, Bart BA. Ultrafiltration for congestive heart failure. Congest Heart Fail.
2009;15(3)136-143.
Contribution: Developed the overall organization of the review, provided key references,
wrote significant portions of the text in collaboration with the co- author.
Impact Factor: Information not available; Sum of times cited: 1
13
18.
Campbell AR, Satran D, Zenovich AG, Campbell KM, Espel JC, Arndt TL, Poulose AK,
Boisjolie CR, Juusola K, Bart BA, Henry TD. Enhanced external counterpulsation
improves systolic blood pressure in patients with refractory angina. Am Heart J.
2008;156(6):1217-1222.
Contribution: Patient recruitment and enrollment for participation in the registry,
assisted with review and editing of manuscript.
Impact Factor: 4.497 in 2012; Sum of times cited: 17
19.
Bart BA, Walsh MM, Blake D, Goldsmith SR. Ultrafiltration for cardiorenal syndrome.
J Card Fail. 2008;14(6):531-532.
Contribution: Study design and concept, intellectual content, database development,
statistical analysis, manuscript preparation.
Impact Factor: 3.320 in 2012; Sum of times cited: 9
20.
Parker JD, Bart BA, Webb DJ, et al. Safety of intravenous nitroglycerin after
administration of sildenafil citrate to men with coronary artery disease: a double-blind,
placebo-controlled, randomized, crossover trial. Crit Care Med. 2007;35:1863-1868.
Contribution: Assisted in cortical development, site principal investigator, screamed and
enrolled patients, personally supervised administration of study drug, review and
analysis of data, review and editing of manuscript.
Impact Factor: 6.124 in 2012; Sum of times cited: 15
21.
Michaels AD, Bart BA, Pinto T, et al. The effects of enhanced external counterpulsation
on time- and frequency-domain measures of heart rate variability. J Electrocardiol.
2007;40 (6):515-521.
Contribution: Principal investigator; developed concept and study design for multicenter,
investigation–initiated trial; manuscript writing, editing and review.
Impact Factor: 1.093 in 2012; Sum of times cited: 7
22.
Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, et al. Ultrafiltration
versus intravenous diuretics for patients hospitalized for acute decompensated heart
failure. J Am Coll Cardiol. 2007;49(6):675-683.
Contribution: Study and protocol development design, intellectual content and concepts,
data analysis, manuscript writing, editing and review.
Impact Factor: 14.086 in 2012; Sum of times cited: 598
23.
Soran O, Kennard ED, Bart BA, Kelsey SF for the IEPR Investigators. Impact of
external counterpulsation treatment on emergency department visits and hospitalizations
in refractory angina patients with left ventricular dysfunction. Cong Heart Fail.
2007;13(1):36-40.
Contribution: Planning for and creating registry database as part of IEPR working
group, intellectual content, manuscript editing and review.
Impact Factor: Information not available; Sum of times cited: 21
24.
Bart BA. Ultrafiltration for heart failure. Cardiol Rev. 2006;23(7):16-19.
Impact Factor: Information not available; Sum of times cited: Information not available.
14
25.
Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized
patients with heart failure: the relief for acutely fluid-overloaded patients with
decompensated congestive heart failure (RAPID-CHF) trial. J Am Coll Cardiol.
2005;46(11):2043-2046.
Contribution: Principal Investigator/Project Leader of this investigator-initiated
multicenter project; produced study concept and design; wrote protocol; obtained
funding; developed forms, procedures and database; selected and defined data elements;
data analysis and manuscript preparation.
Impact Factor: 14.086 in 2012; Sum of times cited: 248
26.
Bart BA, Erlien DA, Herzog CA, Asinger RW. Marked differences between patients
referred for stress echocardiography and myocardial perfusion imaging studies. Am Heart
J. 2005;149(5):888-893.
Contribution: Study design and concept, intellectual content, database development,
statistical analysis, manuscript preparation.
Impact Factor: 4.497 in 2012; Sum of times cited: 9
27.
Satran A, Bart BA, Henry CR, et al. Increased prevalence of coronary artery aneurysms
among cocaine users. Circulation. 2005;111(19):2424-2429.
Contribution: Blinded review of angiograms, database development, review and editing
of manuscript.
Impact Factor: 15.202 in 2012; Sum of times cited: 64
28.
Shah BR, Velazquez E, Shaw LK, Bart BA, O’Conner C, Wagner, GS.
Revascularization improves survival in ischemic cardiomyopathy regardless of
electrocardiographic criteria for prior small-to-medium myocardial infarcts. Am Heart J.
2002;143(1):111-117.
Contribution: Manuscript review and editing.
Impact Factor: 4.497 in 2012; Sum of times cited: 4
29.
Wellan DJ, Shaw LK, Bart BA, Kraus WE, Califf RM, O’Conner CM. Cardiac
rehabilitation and survival in patients with left ventricular systolic dysfunction. Am Heart
J. 2001;142(1):160-166.
Contribution: Database development, manuscript review.
Impact Factor: 4.497 in 2012; Sum of times cited: 20
30.
Shah MR, Granger CB, Bart BA, et al. Sex-related differences in the use and effects of
angiotensin-converting enzyme inhibitors in heart failure: the SPICE (study of patients
intolerant of converting enzyme inhibitors) registry. Am J Med. 2000;109(6):489-492.
Contribution: Review and editing of manuscript.
Impact Factor: 4.768 in 2012; Sum of times cited: 28
31.
Granger CCB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, WarnerStevenson L, Swedberg K, Young J, Yusuf S, Califf RM, Bart BA, et al. Randomized
trial of candesartan cilexetil in the treatment of patients with congestive heart failure and
15
a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J.
2000;139(4):609-617.
Contribution: Study design, wrote protocol, selected data elements and structured
database, international coordination and training of international site investigators and
monitors, international project coordinator (100 sites), review and editing of manuscript.
Impact Factor: 4.497 in 2012; Sum of times cited: 103
32.
Bart BA, Concern for azotemia with angiotensin-converting enzyme inhibitors: public
health implications and clinical relevance. Am Heart J. 1999;138(5) Pt 1:801-803.
Contribution: Intellectual content and manuscript preparation.
Impact Factor: 4.497 in 2012; Sum of times cited: 16
33.
Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left
ventricular systolic dysfunction: results from the study of patients intolerant of converting
enzyme inhibitors (SPICE) registry. Eur Heart J. 1999;20(16):1182-1190.
Contribution: Study design and concept; intellectual content; wrote protocol, developed
forms and database with definition of data elements; international study coordination
(100 sites) and training of investigators; manuscript preparation.
Impact Factor: 14.097 in 2012; Sum of times cited: 125
34.
Bart BA, Goldsmith SG. Aggravated renal dysfunction and the acute management of
advanced chronic heart failure. Am Heart J. 1999(2) Pt 1;138:200-202.
Contribution: Intellectual content and manuscript preparation.
Impact Factor: 4.497 in 2012; Sum of times cited: 16
35.
Shah BR, Lin C, Maynard C, Bart BA, et al. Specificity of electrocardiographic
myocardial infarction screening criteria in patients with nonischemic cardiomyopathies.
Am Heart J. 1998;136(2):314-319.
Contribution: Study design, intellectual content and concept, manuscript editing and
review.
Impact Factor: 4.497 in 2012; Sum of times cited: 2
36.
Gattis WA, Larsen RL, Hasselblad V, Bart BA, O’Connor CM. Is optimal ACE-inhibitor
dosing neglected in elderly heart failure patients? Am Heart J. 1998;136(1):43-48.
Contribution: Manuscript editing and review.
Impact Factor: 4.497 in 2012; Sum of times cited: 54
37.
Bart BA, Shaw LK, McCants CB Jr, et al. Clinical determinants of mortality in patients
with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll
Cardiol. 1997;30(4):1002-1008.
Contribution: Principal investigator, independently developed the concept and study
design, responsible for conduct of the study, data acquisition, analysis, manuscript
preparation.
Impact Factor: 14.086 in 2012; Sum of times cited: 263
16
38.
Bart BA, Gattis WA, Diem SJ, O’Connor CM. Reasons for underuse of angiotensinconverting enzyme inhibitors in patients with heart failure and left ventricular
dysfunction. Am J of Cardiol. 1997;79(8):1118-1120.
Contribution: Principal Investigator, independently developed the concept and study
design, responsible for conduct of the study, data acquisition and analysis, manuscript
preparation.
Impact Factor: 3.209 in 2012; Sum of times cited: 91
39.
Melvin D, Shah BR, Maynard C, Bart BA, Wagner GS. Left ventricular hypertrophy
impairs detection of myocardial infarction in patients with nonischemic cardiomyopathy.
North Carolina Med J. 1997;58(2):134-137.
Contribution: Database design and development, intellectual content of manuscript,
review and editing of manuscript.
Impact Factor: Information not available; Sum of times cited: 6
40.
Bart BA, Wolfel EE. Method of expired gas collection during cardiopulmonary exercise
testing does not affect respiratory gas exchange measurements in patients with heart
failure. J Card Failure. 1994;1(1):91-96.
Contribution: Principal Investigator of this investigator-initiated project, independently
developed the concept and study design, wrote study protocol, responsible for conduct of
study, data acquisition, analysis and manuscript preparation.
Impact Factor: 3.320 in 2012; Sum of times cited: 1
Peer-reviewed publications, accepted for publication
1.
Goldsmith SR, Bart BA, Burnett JC. Decongestive therapy and renal function in acute
heart failure: Time for a new approach? Circ Heart Fail. Accepted for publication, April
2014.
Non peer-reviewed publications
1.
Bart BA, Hernandez AF. Ultrafiltration in Heart Failure with Cardiorenal Syndrome.
N Engl J Med. 2013;368(12):1159-60
2.
Bart BA. Book review. The cardiorenal syndrome: a clinician’s guide to
pathophysiology and management. Circulation. 2012;126.
3.
Bart BA, Goldsmith SR, Boyle A, Costanzo MR. Renal function and ultrafiltration.
J Card Fail. 2008;14(6):533-534.
Contribution: Intellectual content and writing of manuscript.
4.
Bart BA. Advances in Heart Failure, Minnesota’s Role in the NHLBI’s Heart Failure
Network. Minn Med. 2008;40-42.
5.
Bart BA. Heart failure. New treatments can help manage the disease. Minnesota
Healthcare News. 2007;5(6):16-17.
6.
Bart BA. Clinical Tips. IEPR Newsletter. 2005;7(2):5.
17
7.
Bart BA. Quality of life for patients with congestive heart failure. IEPR Newsletter.
2004:6(2):1.
8.
Juusola K, Sigafus M, Smyrak L, Bart BA. IEPR Site Spotlight: Hennepin County
Medical Center. IEPR Newsletter. 2004;6(3):4.
Contribution: Intellectual content, review and editing of manuscript.
9.
Fenstad ER, Boisjolie CR, Henry TD, Bart BA. EECP: an option for "no option" cardiac
patients. Minnesota Physician. 2001;XV(2).
Contribution: Intellectual content, review and editing of manuscript.
10.
Bart BA, O’Connor CM. Clinical determinants of mortality in patients with
cardiomyopathy. Cardiology Review. 1999;16:9-11.
Contribution: Intellectual content and writing of manuscript.
11.
Bart BA, Eisenberg PR. Clinical case studies in heart failure. Edited by O’Connor CM.
New York, Pfizer, April, 1996.
Contribution: Intellectual content and writing of manuscript.
12.
Bart BA. Maximal work capacity elicited by treadmill and ski ergometry in wellconditioned male and female cross-country skiers. Master of Science Thesis. Department
of Physiology, University of Minnesota, Minneapolis, Minnesota, 1989.
Contribution: Wrote protocol, screened and enrolled participants, personally present
during all testing, acquired, reviewed, and analyzed data, wrote thesis.
Book Chapters
1.
Bart BA. Ultrafiltration for the management of volume overload. In: Semigran MJ, Shin
JT, eds. Heart Failure, Second Edition. Boca Raton, Florida: Taylor & Francis Group;
2013:427-444.
Contribution: Intellectual content and manuscript preparation.
2.
Bart BA. Enhanced External Counterpulsation. In: Barsness GW, Holmes DR, eds.
Coronary Artery Disease: New Approaches without Traditional Revascularization.
London, England: Springer; 2012:53-66.
Contribution: Intellectual content and manuscript preparation.
3.
Bart BA, Goldsmith SR. Other Neurohormonal Systems. In: Hosenpud JD, Greenberg
BH, eds. Congestive Heart Failure, 3rd edition. Philadelphia, Pennsylvania: Lippincott
Williams & Wilkins; 2006:193-204.
Contribution: Intellectual content and manuscript preparation.
18
Presentations
Invited Oral Presentations at International Professional Meetings, Conferences
1.
“The Use of Ultrafiltration for the Management of Acute Heart Failure,” International
Renal Replacement Therapy Meeting, Bellvitge Hospital, Barcelona, Spain, October 11,
2013.
Invited Oral Presentations at National Professional Meetings, Conferences
1.
“Effect of heart failure treatment strategies on development of cardiorenal syndrome,"
63rd annual scientific sessions of the American College of Cardiology, Washington DC,
2014.
2.
"Rule of ultrafiltration in acute decompensated heart failure," joint symposium of the
German Cardiac Society and Thai Heart Association and the American College of
Cardiology, 63rd Annual Scientific Sessions of the American College of Cardiology,
Washington, DC, 2014.
3.
“Heart Failure Trials: The Year in Review,” CARRESS-HF 17th Annual Scientific
Meeting, Heart Failure Society of America, Orlando, Florida, September 23, 2013.
4.
“Advantages and Pitfalls of Ultrafiltration Therapy,” American College of
Cardiology’s 61st Annual Scientific Sessions and Expo, Chicago, Illinois, March 25,
2012.
5.
“Hemoconcentration with Ultrafiltration: Good or Bad?” 15th Annual Scientific Meeting,
Heart Failure Society of America, Boston, Massachusetts, September 19, 2011.
6.
“Management of Acute Fluid Overload: Diuretics vs. Aquaphoresis,” Transcatheter
Cardiovascular Therapeutics (TCT) Meeting, Washington, DC, 2007.
7.
“Ultrafiltration Benefits and Mechanisms,” Heart Failure Society of America, 11th
Annual Scientific Meeting, Washington, DC, 2007.
8.
“Heart Failure for the Consultant Cardiologist: 2007 Update,” Session Co-chair, 56th
Annual Scientific Session of the American College of Cardiology, New Orleans,
Louisiana, March 6, 2007.
9.
“Meet the Thought Leaders and Industry Experts on EECP Therapy: A Noninvasive
Therapy for Heart Failure and Angina Pectoris," Meet the Experts, American College of
Cardiology, Satellite Symposia, Orlando, Florida, 2005.
10.
“Therapeutic Ultrafiltration for the Management of Fluid Overload: Current and Future
Role–The RAPID CHF Study,” Satellite Symposium, Heart Failure Society of America,
Las Vegas, Nevada, 2003.
11.
“CAD in Women,” Top Guns of the Future, Disney Institute, Orlando, Florida, 2001.
19
12.
“CAD vs. Non-CAD,” Heart Failure Society of America, 2nd Scientific Meeting, Boca
Raton, Florida, 1998.
13.
“Management of Heart Failure,” Panelist, 15th Edward S. Orgain Cardiovascular
Symposium, Durham, North Carolina, 1996.
14.
“Managing CHF: Staying beyond the Hospital Walls,” Facilitator, Heart Center
Conference, Roundtable Discussion, Durham, North Carolina, 1995.
Invited Oral Presentations at Local and Regional Professional Meetings, Conferences
1.
“Hot Topics from the American College of Cardiology (ACC) 2014,” Medicine Grand
Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, April 24, 2014.
2.
“Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome–The
Creation of a Comparative Effectiveness Trial,” Medicine Grand Rounds, Hennepin
County Medical Center, Minneapolis, Minnesota, December 6, 2012.
3.
“Cardiorenal Syndrome: CARRESS HF Trial Results and Implications,” Heart Failure
2012: The Update, Minnesota Heart Failure Consortium, Edina, Minnesota, December 1,
2012.
4.
“Hypertension Panel,” Panelist, Heartland Summit, Piper Jaffray Headquarters,
Minneapolis, Minnesota, August 16, 2012.
5.
“Heart Failure and Renal Failure,” Heart Failure 2011: The Update, 9th Annual Session of
the Minnesota Heart Failure Consortium, Minneapolis, Minnesota, October 29, 2011.
6.
“NHLBI Heart Failure Clinical Trials Network–Introduction to Selected Ongoing Trials
at Hennepin County Medical Center,” Geriatrics Grand Rounds, Hennepin County
Medical Center, Minneapolis, Minnesota, August 9, 2011.
7.
“Ultrafiltration: How, In Whom, and When to Do It?” Bakken Symposium 2010: Heart
Failure, University of Minnesota, Minneapolis, Minnesota, December 6, 2010.
8.
“Should All Patients with Decompensated Heart Failure and Volume Overload Receive
Ultrafiltration?” Debate, Pro: Bart BA, Con: Walsh M. Heart Failure 2009: The Update,
7th Annual Session of the Minnesota Heart Failure Consortium, Minneapolis, Minnesota,
November 7, 2009.
9.
“Renal Denervation for Hypertension,” Clinical Nephrology Conference, Department of
Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, January 9, 2009.
10.
“Wanted: Dead or Alive; Myocardial Viability Testing,” Medicine Grand Rounds,
Hennepin County Medical Center, Minneapolis, Minnesota, December 11, 2008.
20
11.
“Changes in Renal Function during Heart Failure Therapy: What is the Kidney Trying to
Tell Us?” 30th Annual Cardiovascular Conference, HealthPartners, Saint Paul, Minnesota,
December 4, 2008.
12.
“Cardiorenal Syndrome,” Grand Rounds, Minneapolis Heart Institute, Minneapolis,
Minnesota, November 24, 2008.
13.
“Cardiorenal Syndrome,” Grand Rounds, Minneapolis Veterans Medical Center,
Minneapolis, Minnesota, November 21, 2008.
14.
“Future of Academic Cardiovascular Medicine,” Radisson Hotel, University of
Minnesota, Minneapolis, Minnesota, September, 2008.
15.
“Ultrafiltration for Heart Failure: Mechanisms and Benefits,” 29th Annual Cardiovascular
Conference, HealthPartners, Saint Paul, Minnesota, 2008.
16.
“Ablation of Renal Sympathetic Nervous System Trial,” (Denervation Trial), Hennepin
County Medical Center, Division of Nephrology, Minneapolis, Minnesota, 2007.
17.
“The Stages of Heart Failure,” Mercy Medical Center, Coon Rapids, Minnesota, 2006.
18.
“The Cardiologist’s Role in Heart Failure Stages A-D.” CME Program for Minnesota
Chapter of the American College of Cardiology Annual Meeting, Minneapolis,
Minnesota, 2006.
19.
“Do All Patients with an EF <35% Need an ICD Device?” Debate Speaker, Pro: Alan
Bank, Con: Bart BA, Heart Failure 2006: The Update, Bloomington, Minnesota, 2006.
20.
“Fluid Management in Heart Failure: Leeches, Drugs and Machines,” CHF Solutions,
Inc., Brooklyn Park, Minnesota, 2006.
21.
“Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Grand Rounds,
Saint Paul Heart Clinic, Saint Paul, Minnesota, 2006.
22.
“Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Medicine Grand
Rounds, University of Illinois, Chicago, Illinois, 2006.
23.
“Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Medicine Grand
Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, 2006.
24.
“Fluid Management in Heart Failure: Leeches, Drugs and Machines,” Grand Rounds,
Veterans Administration Medical Center, Minneapolis, Minnesota, 2006.
25.
External Counterpulsation Therapy for Ischemic Heart Disease,” Medicine Grand
Rounds, Hennepin County Medical Center, Minneapolis, Minnesota, 2005.
21
26.
“Nuclear Stress Testing in Clinical Decision Making,” Internal Medicine Grand Rounds,
University of Minnesota, Minneapolis, Minnesota, 2005.
27.
“Ultrafiltration in the Postoperative and Congestive Heart Failure Patients,"
Cardiology/Surgery Conference, United Hospital, Saint Paul, Minnesota, 2005.
28.
“Heart to Heart," Lunchtime Health Series with Hennepin County Medical Center,
Hennepin Faculty Associates and Minneapolis Medical Research Foundation,
Minneapolis, Minnesota, 2005.
29.
“Assessment of Myocardial Viability,” Interventional Cardiology Conference, University
of Minnesota, Minneapolis, Minnesota, 2005.
30.
“Assessment of Myocardial Viability,” Health Partners 28th Annual Cardiovascular
Conference, Saint Paul, Minnesota, 2005.
31.
“Does this Patient with Nonischemic Cardiomyopathy Need a Defibrillator?" Cardiology
Conference, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis,
Minnesota, 2004.
32.
“Infarct Size and Myocardial Perfusion Imaging,” Possis, Inc. Sponsored Event,
Minneapolis, Minnesota, 2004.
33.
“Results of the RAPID Trial,” Investigators’ Meeting, Chicago, Illinois, 2004.
34.
“Results of the RAPID Trial,” Investigators’ Meeting, Minneapolis, Minnesota, 2004.
35.
“Update in Cardiology," East Minneapolis Downtown Council, Minneapolis, Minnesota,
2004.
36.
“Should this Patient get a Defibrillator: Controversies in Cardiology," Scientific and
Business Meeting, American College of Cardiology-Minnesota Chapter, Minneapolis,
Minnesota, 2004.
37.
“Current Therapies for Treating Inpatient CV Disease," Cardiology Noon Conference,
Mercy and Unity Hospitals, Coon Rapids, Minnesota, 2004.
38.
“Setting Up and Running of Stress Lab in Primary Care,” 5th Annual Lillehei
Symposium, University of Minnesota, Minneapolis, Minnesota, 2004.
39.
“Stress Testing Basics: Nuclear Stress Tests,” 5th Annual Lillehei Symposium, University
of Minnesota, Minneapolis, Minnesota, 2004.
40.
“Heart to Heart,” Lunchtime Health Series with Hennepin County Medical Center,
Hennepin Faculty Associates and Minneapolis Medical Research Foundation,
Minneapolis, Minnesota, 2004.
22
41.
“Screening for Coronary Heart Disease,” Scientific Meeting, American College of
Cardiology-Minnesota Chapter, Brooklyn Park, Minnesota, 2003.
42.
Minnesota Medical Research Foundation Brown Bag Seminar Series, Hennepin County
Government Center, Minneapolis, Minnesota, 2003.
43.
“CAD Screening in the Asymptomatic Patient,” 11th Annual Family Practice Update,
Hennepin County Medical Center, Minneapolis, Minnesota, 2002.
44.
“External Counterpulsation for the Treatment of Angina Pectoris.” Cardiology
Conference, North Memorial Heart Center, Minneapolis, Minnesota, 2002.
45.
“External Counterpulsation for the Treatment of Angina Pectoris,” Research Conference,
Fairview-University Medical Center, Minneapolis, Minnesota, 2002.
46.
“Nuclear Cardiac Imaging and Risk Stratification: What You Need to Know,” DuPont
Sponsored Program, Eau Claire, Wisconsin, 2001.
47.
“Angiotensin Receptor Blockers and the RAAS: A Review and Discussion of Potential
Uses in Cardiovascular Diseases,” Merck Sponsored Event, Rapid City, South Dakota,
2001.
48.
“Risk Stratification in Women Using Nuclear Perfusion Imaging,” DuPont Sponsored
Event, Merrillville, Indiana, 2001.
49.
“CAD in Women,” Bristol-Myers Squibb Sponsored Event, Omaha, Nebraska, 2001.
50.
“Risk Stratification and Prognosis of CAD in Special Patient Populations,” Bristol-Myers
Squibb Sponsored Event, South Bend, Indiana, 2001.
51.
Primacor National Advisory Council Dinner Meeting, Co-Chair, Sanofi-Synthelabo
Sponsored Event, Minneapolis, Minnesota, 2001.
52.
“Angiotensin Receptor Blockers–Mechanism of Action and New Applications,” Merck
Sponsored Lecture, Eau Claire, Wisconsin, 2000.
53.
“Nuclear Cardiology–Prognosis and Clinical Implications,” Wausau Hospital Cardiac
Conference, Wausau, Wisconsin, 2000.
54.
“Nuclear Cardiology from the Cardiologist’s Perspective,” Minnesota Radiological
Society Fall Meeting, Minneapolis, Minnesota, 2000.
55.
“Myocardial Profusion Imaging: Update and Prognostic Implications,” Grand Rounds,
University of Minnesota, Minneapolis, Minnesota, 2000.
23
56.
“Angiotensin Receptor Blockers: Mechanisms and New Directions,” Grand Rounds,
Veterans Administration Medical Center, Minneapolis, Minnesota, 1998.
57.
“Nuclear Cardiac Imaging,” Medicine Grand Rounds, Hennepin County Medical Center,
Minneapolis, Minnesota, 1997.
Peer-Reviewed Oral Abstract Presentations at Professional Meetings, Conferences
1.
Parker JD, Bart BA, Webb D, Koren MJ, Siegel RL, Nicholas S. A double-blind,
placebo-controlled, crossover study of the safety of intravenous glycerol trinitrate after
administration of sildenafil citrate to men with coronary artery disease. American College
of Cardiology, Scientific Sessions, Orlando, Florida, 2005.
2.
Shroff GR, Herzog CA, Cen YY, Bart BA. Carotid stiffness index β significantly
correlates with coronary heart disease risk score., American College of Cardiology,
Scientific Sessions, San Francisco, California, 2005.
3.
Bart BA, Shaw LK, McCants CB Jr, et al. Clinical determinants of mortality in
patients with angiographically proven ischemic and nonischemic cardiomyopathy., 69th
Scientific Sessions of the American Heart Association, New Orleans, Louisiana, 1996.
Circulation. 1996;94(8):I-193.
4.
Bart BA, Wolfel EE, Bristow MR. The effect of the method of expired gas collection on
respiratory gas exchange measurements in patients with heart failure., American College
of Sports Medicine 40th Annual Meeting, Seattle, Washington, 1993.
5.
Bart BA. Acute respiratory distress in an asthmatic following adenosine. Winner,
American College of Physicians Associates Clinical Vignette Competition, , American
College of Physicians Annual Meeting, San Diego, California, 1992.
6.
Bart BA, Leon AS. Maximal oxygen uptake (VO2max) by ski ergometry in men and
women collegiate champion cross-country skiers. American College of Sports Medicine
37th Annual Meeting, Salt Lake City, Utah, 1990. J Amer Coll Cardiol. 2001;37(2):7A.
Poster Abstract Presentations at Professional Meetings, Conferences
1.
Yannopoulos D, Mahoney B, Garcia S, Frascone R, Helmer G, Lick C, Conterato
M, Baran K, Roh S, Panetta C, Stark R, Haughland M, Mooney M, Bart BA.
Early access to cardiac catheterization laboratory for patients resuscitated from
cardiac arrest due to a shockable rhythm. The Minnesota Resuscitation
Consortium Twin Cities unified protocol. Circulation. 2013;128:A310.
2.
Bart G, Bart BA, Karim R, Wyman Z. Methadone dose and the QTc interval: little
clinical relevance, big unknowns. Abstract from the 73rd Annual Scientific Meeting,
College on Problems of Drug Dependence, Hollywood, Florida, 2011.
24
3.
Augostini RS, Jagielski D, Ponikowski P, Oldenburg O, Gutleben KJ,
Michalkiewicz D, Karim R, Bart BA, et al. Phrenic nerve stimulation for central sleep
apnea in congestive heart failure does not interfere with the functioning of existing
implantable cardiac devices. Heart Rhythm. 2011;8(5)Suppl1:S61.
4.
Ahmed I, Bart G, Bart BA. Cocaine users hospitalized for acute decompensated
heart failure: falling between the cracks-an opportunity for improved care. J Card
Fail. 2010;16(8):S109.
5.
Abraham WT, Zhang SJ, Michalkiewicz D, Hasan A, Bart BA, et al. Results of
chronic phrenic nerve stimulation using the RespiCardia™ System are
comparable to acute results in the improvement of central sleep apnea. First-inMan Experience, American Heart Association Resuscitation Science Symposium,
Chicago, Illinois, November 2010.
6.
Mulder M, Scott NL, Bart BA, Sprenkle M, Bachour F, Smith SW. Early post
resuscitative care of adult, non-traumatic cardiopulmonary arrests is rarely affected by
routine head computed tomography. American Heart Association Resuscitation Science
Symposium, Chicago, Illinois, November 2010.
7.
Ponikowski P, Witkowski T, Khayat R, Michalkiewicz D, Bart BA, Hasan A, Abraham
WT. A novel approach using phrenic nerve stimulation to treat central sleep apnea. Firstin-Man Experience, 24th Annual Meeting of the Associated Professional Sleep Societies,
LLC, San Antonio, Texas, June 2010.
8.
Mulder M, Bart BA, Smith SW. Faster, cooler, better? A comparison of two methods for
instituting mild therapeutic hypothermia in comatose, out-of-hospital cardiac arrest
patients. Poster Presentation, American College of Cardiology, Scientific Sessions,
Atlanta, Georgia, March 2010.
9.
Ponikowski P, Zhang S, Witkowski T, Hasan A, Khayat R, Bart B, Jagielski D, Zhang
X; Central sleep apnea events are terminated by phrenic nerve stimulation. Poster
Abstract, American College of Cardiology 59th Annual Scientific Session, Atlanta,
Georgia, March 2010. J Am Coll Cardiol. 2010;55(10s1):A30.E289-A30.E289.
10.
Thorsgard M, Bart B, Bachour F. The use of elective vs. urgent or emergent PCi from a
tertiary teaching medical center. Lillehei Heart Institute Symposium, University of
Minnesota, Minneapolis, Minnesota, October 2009.
11.
Bart BA. Predictors and significance of decrease in serum creatinine in heart failure
patients treated for volume overload with diuretics or ultrafiltration. 12th Annual
Scientific Meeting of the Heart Failure Society of America, Toronto, Ontario, Canada,
September, 2008.
12.
Mulder M, Franco MP, Smith S, Goldsmith SR, Bart BA. Potential impact for
therapeutic hypothermia for adult out-of-hospital cardiac arrest survivors at HCMC.
25
10th Annual Department of Medicine Research Day, University of Minnesota,
Minneapolis, Minnesota, May 2008.
13.
Henry T, Satran D, Campbell A, Johnson R, Poulose A, Hodges J, Bart BA, et al.
Long-term mortality in patients with refractory angina. Poster Abstract, American
College of Cardiology 57th Annual Scientific Session, Chicago, Illinois, 2008.
14.
Guglin ME, Bart BA, Fang J, et al. Predictors and significance of decrease in
serum creatinine in heart failure patients treated for volume overload with
diuretics or ultrafiltration. J Card Fail. 2008;16(6)Suppl1:S72.
15.
Henry, TD, Satran D, Campbell AR, Johnson RJ, Poulose AK, Hodges J, Bart BA,
et al. Long-term mortality in patients with refractory angina. J Am Coll Cardiol.
2008;51(10)SupplA:A227.
16.
Bart BA, Fang, JC, Guglin M. Changes in GFR, BUN and BUN/creatinine during
treatment of heart failure and volume overload with ultrafiltration or intravenous
diuretics. J Am Coll Cardiol. 2008;51(10)SupplA:A48.
17.
Bart BA, Insel J, Goldstein MM, et al. The improved outcomes following
ultrafiltration versus intravenous diuretics in UNLOAD are not solely due to
increased weight loss in the ultrafiltration group. J Card Fail.
2007;13(6)Suppl2:S188(399).
18.
Costanzo MR, Bart BA, Anderson A, Sobotka PA. Differential response to ultrafiltration and intravenous diuretics in decompensated heart failure patients with
preserved versus reduced systolic function. J Card Fail. 2007;13(6)Suppl2:S180(368).
19.
Bart BA, Teerlink JR, Costanzo MR, Saltzberg MT, Sobotka PA. Changes in
serum creatinine during treatment of heart failure and volume overload with
ultrafiltration or intravenous diuretics. J Card Fail. 2006;12(6)Suppl:S114.
20.
Thakkar BV, Hirsch AT, Bart BA, et al. The efficacy and safety of EECP in
patients with peripheral arterial disease., American College of
Cardiology, Scientific Sessions, Atlanta, Georgia, 2006. J Am Coll Cardiol.
2006;47(4)SupplA:348A.
21.
Campbell AR, Zenovich AG, Campbell KM, Espel JC, Streufert TL, Poulose AK,
Boisjolie CR, Juusola K, Bart BA, Henry TD. Enhanced external counterpulsation
provides acute and sustained hemodynamic benefits in refractory angina. Electronic
Poster Presentation, TCP Scientific Sessions, 2006.
22.
Smith SW, Jackson EA, Hanson KK, Bart BA. Incidence of MI in ED chest pain patients
with a recent negative stress imaging test. Poster Presentation. Society of Academic
Emergency Medicine. 2005;12(5).
26
23.
Shroff GR, Bart BA. Radiation-induced myocardial dysfunction: a "stunning"
phenomenon. Poster Presentation, American College of Physicians-Minnesota Chapter,
Scientific Sessions, Minneapolis, Minnesota, 2004.
24.
Bogonko E, Larsen K, Bart BA. An "irregular" manifestation of hypoglycemia: a unique
case of atrial fibrillation in a young diabetic. Poster Presentation, American College of
Physicians-Minnesota Chapter, Minneapolis, Minnesota, 2004.
25.
Bart BA, Boyle A, Bank AJ, et al. Randomized controlled trial of ultrafiltration versus
usual care for hospitalized patients with heart failure: preliminary report of the RAPID
trail. Moderated Poster Presentation, Heart Failure Society of America, Toronto, Ontario,
Canada, 2004. J Card Fail. 2004;10(4)Suppl:S23.
26.
Mohn JN, Asinger RW, Herzog CA, Bart BA. Echocardiographic correlates in 2337
patients with pulmonary hypertension., American College of Cardiology, New Orleans,
Louisiana, March 2004. J Amer Coll Cardiol. 2004;43(5)Suppl A:518A.
27.
Bardo A, Bart BA. Something doesn’t click: two cases of sub-acute prosthetic
valve thrombosis. Presented at American College of Cardiology Clinical Vignettes,
November 2003.
28.
Shroff G, Hanchate V, Chaubal N, Bornstein B, Bart BA, Karnad D. Noninvasive
measurement of stiffness of large arteries in Takayasu’s disease using the stiffness
index. Presented at American College of Cardiology Clinical Vignettes, November 2003.
29.
Schneider E, Bart BA. Balanced ischemia: a not so fine balance. Presented at
American College of Cardiology Clinical Vignettes, 2003.
30.
Schneider E, Bart BA. Balanced ischemia: a not so fine balance. Winner, Regional
American College of Physicians Poster Session, Minneapolis, Minnesota, 2002.
31.
Koralesky A, Bart BA, Apple F, Henry TD, et al. Is troponin I a risk factor for poor
outcome in pulmonary embolus? Presented at World Congress of Cardiology, Sydney,
Australia, May 2002.
32.
Bart BA, Erlien DD, Asinger RW, Stuart DD, Herzog CA. Differential selection of stress
echo and stress SPECT studies in patients with known or suspected ischemic heart
disease. J Nucl Cardiol. 2002;9(4):2.27.
33.
Koralesky A, Bart BA, Apple F, Henry TD. Is troponin I a risk factor for poor outcome
in pulmonary embolism? J Amer Coll Cardiol. 2002;39(5):212A.
34.
Herzog CA, Huiras BE, Bart BA. Are nuclear myocardial perfusion and
echocardiography (ECHO) stress imaging studies equivalent in the assessment of
coronary artery disease in patients with end stage renal disease? J Am Soc Nephrol.
2001;12(2):383A-384A.
27
35.
Bart BA, Herzog CA, Boisjolie CR, Peterson-Norby K, Henry TD. Stress
echocardiography and nuclear perfusion imaging to assess response to angiogenesis
therapy: a double-blind, placebo controlled clinical trial. J Amer Coll Cardiol.
2001;37(2):A7.
36.
Henry TD, McKendall GR Azrin MA, Lopez JJ, Benza R, Willerson JT, Giacomini J,
Olson R, Bart BA, Roel JP, Annex BH. VIVA trial: one year follow up. Circulation.
2000;102:II-309.
37.
Satran A, Bart BA, Murad B, Henry T. Prevalence of coronary artery aneurysm
in cocaine users. American Heart Association Scientific Sessions. Circulation.
1999;100:I-557.
38.
Whellan DJ, Shaw LK, Bart BA, et al. Cardiac rehabilitation is associated with
improved survival in CHF patients. Circulation. 1998;98(1)Suppl I:I-774.
39.
Satran A, Bart BA, Murad B, Henry T. Prevalence of coronary artery aneurysm in
cocaine users. Presented at State and National American College of Physicians Meetings,
September 1998.
40.
Larsen RL, Murdock DD, Skyes AM, Barrett SK, Hansley KM, Bart BA, et al.
Are there biases against recruitment of the elderly and women in congestive heart
failure (CHF) trials? Council on Geriatric Cardiology, Atlanta, Georgia, 1998.
41.
Bart BA, Ertl G, Kuch J, et al. Contemporary management of patients with left
ventricular dysfunction: preliminary results from the study of patients intolerant
of converting enzyme inhibitors (SPICE) registry. Poster Presentation, 19th
Congress of the European Society of Cardiology, Stockholm, Sweden, August
1997. Eur Heart J. 1997;18(abst. sup):402.
42.
Gattis WA, Larsen RL, Hasselblad V, Bart BA, O’Connor CM. Is optimal ACE inhibitor
dosing neglected in elderly heart failure patients? Poster Presentation, Council on
Geriatric Cardiology, 3rd Annual Scientific Session, Anaheim, California, 1997. Am J
Geriatr Cardiol. 1997;6:44.
43.
Bart BA, Diem SJ, O’Connor CM. Why are heart failure patients with left ventricular
dysfunction not receiving angiotensin-converting enzyme inhibitors? J Am Coll Cardiol.
1997;29(2)Suppl A:167A.
44.
Bart BA. Study of patients intolerant to converting enzyme inhibitors (SPICE): overview
and trial design. 1st Place Poster, 15th Edward S. Orgain Cardiovascular Symposium,
Durham, North Carolina, 1996.
45.
Bart BA, Shaw LK, McCants CB Jr, et al. The clinical and angiographic
diagnosis of ischemic cardiomyopathy: a need to reassess our diagnostic criteria.
28
Poster Presentation, 69th Scientific Sessions of the American Heart Association,
New Orleans, Louisiana, 1996. Circulation. 1996;94(8):I-338.
46.
Chin MH, Connors AF Jr, Vidaillet H, Phillips R, Bellamy P, Bart BA, Goldman L.
Predicting six-month mortality in patients admitted with severe congestive heart failure.
Annual Meeting of the Society for Medical Decision Making, Toronto, Ontario, Canada,
1996.
47.
Bart BA, Galanos AN, Mooney R, O’Connor CM. Elderly patients admitted for heart
failure receive less aggressive care than their younger counterparts. Poster Presentation,
Council on Geriatric Cardiology 2nd Annual Scientific Session, Orlando, Florida, 1996.
Am J of Geriatr Cardiol. 1996;5(2):58.
48.
Vance JC, Bart BJ, Bart BA, et al. Effectiveness of intralesional human recombinant
alfa-2b interferon (Intron-A) for the treatment of patients with condyloma acuminatum.
Clin Res. 1986;34(4):993A.
29
Bradley A. Bart, M.D., F.A.C.C.
7. SERVICE
a. Percent effort 60%
b. Narrative Summary
As a clinical cardiologist and Director of the Division of Cardiology at Hennepin County
Medical Center (HCMC), the focus of my service to HCMC and the University of Minnesota has
been on providing excellent clinical care and supporting the educational mission of HCMC and
the University of Minnesota, as well as a fulfilling a number of leadership roles.
I have been Director of the Division of Cardiology at HCMC since 2008, leading a group of 10
cardiologists who provide cardiovascular services to Hennepin Healthcare System, Inc.,
including preventive cardiology, interventional cardiology, electrophysiology, heart failure
management, inpatient consults, advanced imaging (including CT, MRI, echo, and nuclear), and
cardiac rehabilitation. This is a diverse group of physicians with backgrounds representing
Ethiopia, Pakistan, India, Syria, and the United States.
In my role as Director of the Division of Cardiology, I oversee operations with the medical
directors and administrators in the inpatient service areas, cardiology clinic, echo lab, cardiac
catheterization lab, electrophysiology lab, ECG lab, and cardiac rehabilitation.
In January of 2013, I was asked by the Chief of Clinical Operations and the Chief Nursing
Officer for Hennepin Healthcare Systems to serve as the co-lead of a new cardiovascular service
line at HCMC - integrating the activities of the Division, critical care, and cardiovascular
surgery. In this capacity, I have developed an organizational structure and reporting process that
has enhanced communication across the service line and established protocols, reporting tools,
quality metrics, and a strategic plan for growth focusing on improving access for primary care.
I have also served on a number of hospital committees and working groups. I was elected to the
Hennepin Faculty Associates Board of Directors and served the physician practice group
representing the Department of Medicine from 2000 to 2003 and again from 2011 to 2012. I was
a member of the Minnesota Medical Research Foundation Peer Review Committee, the Chief of
Medicine and the Chief of General Internal Medicine Search Committees, and the Core
Measures Working Groups for Heart Failure and Acute Myocardial Infarction.
The hospital (HCMC) and the physician practice group (HFA) integrated in 2012 to become
Hennepin Healthcare System, Inc. (HHS). I was elected by my peers to serve on the Physicians'
Compensation and Benefits Subcommittee (PCBS). This committee, including 4 voting
physicians, developed the physician compensation and incentive plan that was recommended to
the HHS Board of Directors after integration. The PCBS continues to meet to review and revise
recommendations to the HHS Board concerning compensation.
I also serve on the Graduate Medical Education Committee representing the Department of
Medicine and the Fellowship Training Program in Cardiovascular Disease as the Program
1 Director; and am the Co-Chair of the heart failure and acute myocardial core measures working
groups.
I am an Associate Editor for the Journal of Cardiac Failure, on the Editorial Board for the
Journal of the American College of Cardiology, and review papers for the European Journal of
Cardiology, Circulation Heart Failure, and the American Heart Journal. I also served on the
NHLBI Heart Failure Network Ancillary Studies Committee from 2008 to 2012.
My clinical activities consume approximately 50-60% of my time. I served as the medical
director for nuclear cardiac imaging at both the University of Minnesota, from 2001 to 2007, and
Hennepin County Medical Center from 1997 to the present. I started several clinical programs at
Hennepin County Medical Center and continue to serve as medical director for these initiatives,
which include the enhanced external counterpulsation program for patients with chronic
ischemic heart disease, therapeutic hypothermia for survivors of out of the hospital cardiac
arrest, and slow continuous ultrafiltration for patients with acute heart failure. Clinically, I
attend on the inpatient cardiology consultation 10 weeks per year, see patients in clinic 3 - 4 half
days per week including heart failure clinic, primary cardiology clinic, early access clinic, and
outreach clinic in Brooklyn Center. I also read ECGs 5 days per month and cardiac CT and
myocardial SPECT studies 6 days per month.
I have been active in community educational efforts, including presenting at a number of
programs throughout the region including: Grand Rounds at the University of Minnesota, the VA
Medical Center, Abbott Northwestern Hospital, Mercy Hospital, St. Paul Heart Clinic, North
Memorial Hospital, and the University of Illinois. I have been invited to give talks at the Health
Partners Annual Cardiovascular Conference, the Minnesota Chapter of the American College of
Cardiology, the East Minneapolis Downtown Council, the Annual Lillehei Symposium, the
Annual Bakken Symposium, and the Minnesota Radiological Society.
I have been on the Advisory Board of the Minnesota Heart Failure Consortium since its founding
in 2002. In this role, I help plan the annual continuing medical education meetings and
frequently speak at this well-attended CME-accredited meeting for physicians and nurses. I have
spoken in the Heart-to-Heart lunchtime health series sponsored by the Minneapolis Medical
Research Foundation in downtown Minneapolis and have had numerous appearances on local
radio (Healthy Matters, WCCO), television, and newspapers for cardiology related topics of
interest to the lay public.
c. Clinical Service
Clinical Leadership Accomplishments

Established a Cardiovascular Service Line at Hennepin County Medical Center in 2013.

Established Fellowship Training program in cardiovascular disease at Hennepin County
Medical Center in 2011.

Served as Chief of Cardiology at Hennepin County Medical Center since 2008.

Established therapeutic Hypothermia Program (first in Minnesota) for cardiac arrest
patients at Hennepin County Medical Center, 2004.
2 


Established Ultrafiltration Program (first in Minnesota) for acute heart failure at
Hennepin County Medical Center, 2004.
Established Enhanced External Counterpulsation Program (first in Minnesota) for severe
ischemic heart disease at Hennepin County Medical Center, 2002.
Established the Nuclear Cardiac Imaging Program and clinical database for nuclear stress
testing at Hennepin County Medical Center, 1997.
Quality Improvement Projects

Co-Chair of Heart Failure and Acute MI core measures working groups – achieving
> 95% compliance with core measures in these areas.

Co-Chair of Cardiovascular Service Line improving surgical outcomes and increasing
growth by 23% in first year of program.

Clinical service responsibilities
o 10 weeks per year attending on inpatient cardiology consultation service
o 3-4 half days of clinic per week (personal, heart failure, early access, and
outreach)
o ECG reading 5 days/month
o Nuclear perfusion imaging and coronary CT angiography 6 days/month.
d. Discipline-Related, Professional Service
Editorships/Journal Reviewer Experience
Reviewer, Circulation: Heart Failure
Editorial Board Member, Journal of the American
College of Cardiology: Heart Failure
Associate Editor, Journal of Cardiac Failure
Reviewer, European Journal of Heart Failure
2010-Present
2000-Present
Other Service Experiences
Steering Committee for AVOID HF clinical trial
Member, Advisory Board, Minnesota Heart Failure Consortium
Member, International EECP Patient Registry Writing Group
2008-Present
2002-Present
2001-2007
2012-Present
2012-Present
Review Panels for External Funding Agencies, Foundations, etc.
Ancillary Studies Committee for the NIH/NHLBI Heart Failure Network 2008-2012
Organization of Conferences, Workshops, Panels, Symposia
Member, Advisory Board of Minnesota Heart Failure Consortium,
assisted in planning annual CME accredited educational symposia
Committee Memberships
Member, Physician Compensation and Benefits Subcommittee for
Hennepin Healthcare System (HHS), Inc., Board, Minneapolis,
Minnesota
3 2002-Present
2012-Present
Member, Graduate Medical Education Committee, Hennepin
County Medical Center, Minneapolis, Minnesota
2011-Present
Member, Board of Directors, Hennepin Faculty Associates,
Minneapolis, Minnesota
2011-2012
Hospitals and Communities Moving Forward with Patient and Family
Centered Care, Madison, Wisconsin
2011
Member, Search Committee for the Director of the General Internal
Medicine Division, Hennepin County Medical Center, Minneapolis,
Minnesota
2009
Co-Chair, Heart Failure Core Measures Working Group, Hennepin
County Medical Center, Minneapolis, Minnesota
2008-Present
Co-Chair, Acute MI Core Measures Working Group, Hennepin County
Medical Center, Minneapolis, Minnesota
2008-Present
Ancillary Studies Committee for the NIH/NHLBI Heart Failure Network 2008-Present
Member, Minnesota Medical Research Foundation Peer Review
Committee, Minneapolis, Minnesota
2001-2012
Member, Chair of Internal Medicine Search Committee, Hennepin
County Medical Center, Minneapolis, Minnesota
2001
Member, Board of Directors, Hennepin Faculty Associates,
Minneapolis, Minnesota
2000-2003
Member, Cardiology/IRIS Committee, Hennepin County Medical
Center, Minneapolis, Minnesota
2000
Member, Internal Medicine/Hennepin Faculty Associates Cardiology
Task Force, Minneapolis, Minnesota
2000
Member, Medical Service Quality Improvement Committee, VA
Medical Center, Denver, Colorado
1993-1994
Chair, Timeliness and Delinquencies Subcommittee of the Medical
Record Committee, VA Medical Center, Denver, Colorado
1993-1994
Department/Unit Service
Co-Chair, Cardiovascular Service Line, Hennepin County Medical
Center, Minneapolis, Minnesota
4 2013-Present
Program Director, Cardiology Fellowship, Hennepin County Medical
Center, Minneapolis, Minnesota
2011-Present
Director, Division of Cardiology, Department of Medicine,
Hennepin County Medical Center, Minneapolis, Minnesota
2008-Present
Co-Chair, Acute MI Core Measures Working Group, Hennepin County
Medical Center, Minneapolis, Minnesota
2008-Present
Co-Chair, Heart Failure Core Measures Working Group, Hennepin
County Medical Center, Minneapolis, Minnesota
2008-Present
HCMC Site Rotation Director for University of Minnesota Cardiology
Fellowship Program, Hennepin County Medical Center, Minneapolis,
Minnesota
2001-2010
Member, Hennepin Faculty Associates, Board of Directors,
Minneapolis, Minnesota
2011-2012
2000-2003
e. University Service
Member, Cardiology Fellowship Selection Committee, University of
Minnesota, Minneapolis, Minnesota
2001-2010
Rotation Director, Nuclear Cardiac Imaging Rotation for Cardiology
Fellows, University of Minnesota, Minneapolis, Minnesota
2002-2007
University of Minnesota Cardiology Fellowship Selection Committee,
University of Minnesota, Minneapolis, Minnesota
2001-2010
f. Other Service
Community Outreach Activities
1.
Interview, “HCMC Doctor Warns Shoveling Snow Can Lead to Heart Attacks.”
Channel 5 Eyewitness News, Minneapolis, Minnesota, February 20, 2014.
http://kstp.com/article/stories/s3334039.shtml
2.
Interview, “Are marathoners running into heart trouble?” Article by Jeff Strickler, Star
Tribune, Minneapolis, Minnesota, June 14, 2013.
http://www.startribune.com/lifestyle/health/211578741.html
3.
Speaker, Annual Bakken Symposium 2010
4.
Guest, WCCO News Radio “Healthy Matters with Hennepin County Medical CenterHeart Health,” Minneapolis, Minnesota, February 8, 2009.
5 5.
Medicine Grand Rounds at the University of Minnesota, VA Medical Center, Abbott
Northwestern Hospital, Mercy Hospital, St. Paul Heart Clinic, North Memorial Hospital,
and the University of Illinois.
6.
Speaker, HealthPartners Annual Cardiovascular Conference 2005, 2008
7.
Speaker, East Minneapolis Downtown Council 2004 (one presentation)
8.
Speaker, Annual Lillehei Symposium 2004, 2009
9.
Speaker, Heart-to-Heart Lunchtime Health Series sponsored by the Minneapolis Medical
Research Foundation 2004, 2005 (one time per year)
10.
Speaker, Minnesota Radiological Society 2000 (one presentation)
Miscellaneous interviews with local TV, newspapers, and magazines including StarTribune, St.
Paul Pioneer Press, Minneapolis/St.Paul Magazine, Minnesota Monthly, Minnesota Business
Monthly.
6